

CITATION REPORT

List of articles citing

Selective inhibition of BET bromodomains

DOI: 10.1038/nature09504
Nature, 2010, 468, 1067-73.

Source: <https://exaly.com/paper-pdf/48503773/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2263	The Gatekeeper Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains.		
2262	Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.		
2261	Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.		
2260	Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.		
2259	Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.		
2258	ProteinProtein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery.		
2257	.		
2256	Cosolvent-Based Protein Pharmacophore for Ligand Enrichment in Virtual Screening.		
2255	.		
2254	Heroic Bureaucracies. 1991 , 23, 123-147		7
2253	Purification and characterization of two forms of a high-molecular-weight cysteine proteinase (porphyain) from <i>Porphyromonas gingivalis</i> . 1994 , 176, 4549-57		60
2252	Drug discovery: Reader's block. <i>Nature</i> , 2010 , 468, 1050-1	50.4	6
2251	Lose weight with traditional chinese medicine? Potential suppression of fat mass and obesity-associated protein. 2011 , 29, 471-83		16
2250	BRD4 jump-starts transcription after mitotic silencing. 2011 , 12, 133		8
2249	Epigenetic regulation of satellite cell activation during muscle regeneration. 2011 , 2, 18		48
2248	Therapeutic prospects for epigenetic modulation. 2011 , 15, 729-40		20
2247	Differentiation of NUT midline carcinoma by epigenomic reprogramming. 2011 , 71, 2686-96		140

2246	3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. 2011 , 54, 6761-70	177
2245	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. <i>Nature</i> , 2011 , 478, 529-33	50.4 1144
2244	First Honorary Medal of the Signal Transduction Society (STS) and 'CELL COMMUNICATION AND SIGNALING' awarded to Professor Anthony J. (Tony) Pawson. 2011 , 9, 3	2
2243	Getting pharmaceutical R&D back on target. 2011 , 7, 335-9	197
2242	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. <i>Nature</i> , 2011 , 478, 524-850.4	1398
2241	First drugs found to inhibit elusive cancer target. 2011 , 17, 1325	15
2240	Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. 2011 , 7, 2899-908	117
2239	Transforming ligands into transcriptional regulators: building blocks for bifunctional molecules. 2011 , 40, 4286-94	18
2238	BET bromodomain inhibition as a therapeutic strategy to target c-Myc. 2011 , 146, 904-17	2045
2237	Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. 2011 , 13, 1295-304	183
2236	Combinatorial readout of dual histone modifications by paired chromatin-associated modules. 2011 , 286, 18363-8	49
2235	Function of histone deacetylase inhibitors in inflammation. 2011 , 31, 233-63	63
2234	Epigenetics and B-cell lymphoma. 2011 , 18, 293-9	54
2233	The design and application of target-focused compound libraries. 2011 , 14, 521-31	82
2232	The importance of epigenetics in the development of chronic obstructive pulmonary disease. 2011 , 16, 1056-63	23
2231	A decade of exploring the cancer epigenome - biological and translational implications. 2011 , 11, 726-34	2002
2230	ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. 2011 , 21, 396-420	607
2229	Comprehensive lysine acetylomes emerging from bacteria to humans. 2011 , 36, 211-20	135

2228	Intrinsically disordered proteins: regulation and disease. 2011 , 21, 432-40	422
2227	Recognition of non-methyl histone marks. 2011 , 21, 761-6	5
2226	DNA demethylases: a new epigenetic frontier in drug discovery. 2011 , 16, 683-90	34
2225	What makes a good drug target?. 2011 , 16, 1037-43	100
2224	Peptoid ligands that bind selectively to phosphoproteins. 2011 , 21, 4960-4	21
2223	Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. 2011 , 20, 287-8	22
2222	Discovery and characterization of small molecule inhibitors of the BET family bromodomains. 2011 , 54, 3827-38	274
2221	Curing "incurable" cancer. 2011 , 1, 477-80	6
2220	Small-molecule ligands of methyl-lysine binding proteins. 2011 , 54, 2504-11	106
2219	Druggability of methyl-lysine binding sites. 2011 , 25, 1171-8	47
2218	The biology of lysine acetylation integrates transcriptional programming and metabolism. 2011 , 8, 12	51
2217	Störung von Histon-Ablesern. 2011 , 123, 5921-5923	1
2216	Disrupting the reader of histone language. 2011 , 50, 5801-3	12
2215	Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. 2011 , 18, 495-507	87
2214	In the heart of a dynamic chromatin. 2011 , 18, 410-2	
2213	G-protein coupled receptor and kinase targets: advances in drug discovery from molecular to clinical. 2011 , 3, 1097-100	2
2212	Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. 2011 , 16, 1170-85	41
2211	Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies?. 2011 , 6, 393-404	33

2210	Targeting MYC dependence in cancer by inhibiting BET bromodomains. 2011 , 108, 16669-74	846
2209	K-acetylation and its enzymes: overview and new developments. 2011 , 206, 1-12	25
2208	Bromodomains as therapeutic targets. 2011 , 13, e29	327
2207	Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. 2011 , 31, 2632-40	89
2206	Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. 2011 , 108, E159-68	162
2205	Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. 2011 , 286, 27663-75	40
2204	Bromodomain brake on AML. 2011 , 4, 867-867	
2203	RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus. 2011 , 7, e1002334	38
2202	Low-hanging fruit: targeting Brdt in the testes. 2012 , 31, 3788-9	7
2201	Bromodomain-Containing Protein 4: A Dynamic Regulator of Breast Cancer Metastasis through Modulation of the Extracellular Matrix. 2012 , 2012, 670632	19
2200	A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation. 2012 , 8, e1003047	70
2199	Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication. 2012 , 8, e1003021	58
2198	Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. 2012 , 4, 904-44	29
2197	Editorial: Space flight modifies T cell activation in the absence of microgravity. 2012 , 92, 1125-6	13
2196	Tendon injuries of the hand in athletes. 2012 , 11, 201-213	1
2195	Editorial: Yin-Yang of EP receptor expression. 2012 , 92, 1129-31	5
2194	Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. 2012 , 287, 36609-16	148
2193	Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner. 2012 , 18, 4679-84	37

2192	The histone code and treatments for acute myeloid leukemia. 2012 , 366, 960-1	7
2191	Regulation of allergic responses to chemicals and drugs: possible roles of epigenetic mechanisms. 2012 , 130, 60-9	9
2190	Annotating MYC status with 89Zr-transferrin imaging. 2012 , 18, 1586-91	75
2189	Tensha therapeutics. 2012 , 30, 305	4
2188	Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. 2012 , 109, 19408-13	278
2187	Editorial: JQ1: giving HIV-1 expression a boost by blocking bromodomains?. 2012 , 92, 1127-9	0
2186	Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. 2012 , 109, 14532-7	147
2185	Clinicopathologic features and long-term outcomes of NUT midline carcinoma. 2012 , 18, 5773-9	249
2184	Down-regulation of NF- κ B transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. 2012 , 287, 28840-51	160
2183	Cell biology: a key driver of therapeutic innovation. 2012 , 199, 571-5	1
2182	Inflammasome signaling in pathogenesis of lung diseases. 2012 , 18, 2320-8	10
2181	Structural genomics: Open collaboration is key to new drugs. <i>Nature</i> , 2012 , 491, 40	50.4 1
2180	NUT midline carcinomas of the sinonasal tract. 2012 , 36, 1216-21	100
2179	Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. 2012 , 36, 1222-7	85
2178	HIV-1 Tat Binding to PCAF Bromodomain: Structural Determinants from Computational Methods. 2012 , 1, 277-96	8
2177	Cancer research: Open ambition. <i>Nature</i> , 2012 , 488, 148-50	50.4 7
2176	Epigenetics in asthma and COPD. 2012 , 94, 2231-41	48
2175	Structure-activity relationships of methyl-lysine reader antagonists. 2012 , 3, 45-51	29

2174	Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. 2012 , 2, 985-94	15
2173	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. 2012 , 120, 2843-52	298
2172	Perceiving the epigenetic landscape through histone readers. 2012 , 19, 1218-27	549
2171	Proteogenomic characterization and mapping of nucleosomes decoded by Brd and HP1 proteins. 2012 , 13, R68	68
2170	Identification and characterization of small molecule inhibitors of a plant homeodomain finger. 2012 , 51, 8293-306	70
2169	Reawakening fetal hemoglobin: prospects for new therapies for the β globin disorders. 2012 , 120, 2945-53	130
2168	Small-molecule inhibition of BRDT for male contraception. 2012 , 150, 673-84	277
2167	Contraception for men: a breakthrough new approach. 2012 , 150, 667-8	10
2166	Reactivation of latent HIV-1 by inhibition of BRD4. 2012 , 2, 807-16	187
2165	Dissecting fragment-based lead discovery at the von Hippel-Lindau protein: hypoxia inducible factor 1 β protein-protein interface. 2012 , 19, 1300-12	129
2164	Structural characterization and inhibition of the Plasmodium Atg8-Atg3 interaction. 2012 , 180, 551-62	36
2163	Patent Highlights. 2012 , 1, 29-35	1
2162	539 BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. 2012 , 48, 166	
2161	538 Finding New Signalling Pathways That Contribute to Cancer Pathogenesis. 2012 , 48, 166	
2160	Genital human papillomavirus infections: current and prospective therapies. 2012 , 93, 681-691	69
2159	The role of protein structural analysis in the next generation sequencing era. 2014 , 336, 67-98	12
2158	Inhibition of bromodomain-mediated protein-protein interactions as a novel therapeutic strategy. 2012 , 3, 123-134	21
2157	The rise of epigenetic targets for the development of novel antivirals. 2012 , 10, 1359-61	4

2156	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. 2012 , 55, 9831-7	157
2155	Place your BETs: the therapeutic potential of bromodomains. 2012 , 33, 146-53	156
2154	New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy. 2012 , 18, 5163-71	12
2153	DNA methylation profiling in the clinic: applications and challenges. 2012 , 13, 679-92	579
2152	Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. 2012 , 55, 9393-413	140
2151	Association of bromodomain BET proteins with chromatin requires dimerization through the conserved motif B. 2012 , 125, 3671-80	41
2150	Plane of best fit: a novel method to characterize the three-dimensionality of molecules. 2012 , 52, 2516-25	71
2149	Emerging epigenetic targets and therapies in cancer medicine. 2012 , 2, 405-13	90
2148	Scaling the druggability landscape of human bromodomains, a new class of drug targets. 2012 , 55, 7342-5	19
2147	The bromodomain interaction module. 2012 , 586, 2692-704	267
2146	Histone recognition and large-scale structural analysis of the human bromodomain family. 2012 , 149, 214-31	1054
2145	Cancer epigenetics: from mechanism to therapy. 2012 , 150, 12-27	1932
2144	Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. 2012 , 15, 21-38	192
2143	Targeting epigenetic readers in cancer. 2012 , 367, 647-57	315
2142	Epigenetic chemical probes. 2012 , 92, 689-93	23
2141	BET domain co-regulators in obesity, inflammation and cancer. 2012 , 12, 465-77	489
2140	Epigenomics and interindividual differences in drug response. 2012 , 92, 727-36	92
2139	Linking epithelial-to-mesenchymal-transition and epigenetic modifications. 2012 , 22, 404-10	25

2138	Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. 2012 , 33, 563-70	49
2137	Everybody's welcome: The big tent approach to epigenetic drug discovery. 2012 , 9, e75-e81	3
2136	Bromodomains: a new target class for small molecule drug discovery. 2012 , 9, e111-e120	25
2135	The therapeutic potential of acetyl-lysine and methyl-lysine effector domains. 2012 , 9, e101-e110	8
2134	Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. 2012 , 17, 1242-8	14
2133	Histone recognition by human malignant brain tumor domains. 2012 , 423, 702-18	45
2132	Bromodomains: are readers right for epigenetic therapy?. 2012 , 3, 691-4	25
2131	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. 2012 , 8, 905-912	84
2130	Small molecule bromodomain inhibitors: extending the druggable genome. 2012 , 51, 1-55	35
2129	Current trends in epigenetic drug discovery. 2012 , 4, 2029-37	3
2128	Protein-Protein Interactions as Drug Targets. 2012 , 1-55	3
2127	Disordered epigenetic regulation in MLL-related leukemia. 2012 , 96, 428-37	46
2126	540 Regulation and Function of the Nek11 Kinase in Colorectal Cancer. 2012 , 48, 166	
2125	Epigenetic alterations in hematopoietic malignancies. 2012 , 96, 413-27	42
2124	Epigenetik in der Onkologie. 2012 , 15, 10-18	
2123	High-throughput strategy to identify inhibitors of histone-binding domains. 2012 , 512, 161-85	2
2122	Pathogenesis of NUT midline carcinoma. 2012 , 7, 247-65	185
2121	Epigenomics Impact for Drug Safety Sciences. 2012 , 365-385	3

2120	Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. 2012 , 287, 43137-55	127
2119	Targeting the epigenome for treatment of cancer. 2012 , 31, 3827-44	46
2118	Determining PTEN functional status by network component deduced transcription factor activities. 2012 , 7, e31053	9
2117	SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. 2012 , 7, e33834	81
2116	Activation of JNK triggers release of Brd4 from mitotic chromosomes and mediates protection from drug-induced mitotic stress. 2012 , 7, e34719	5
2115	Differential scanning fluorometry signatures as indicators of enzyme inhibitor mode of action: case study of glutathione S-transferase. 2012 , 7, e36219	24
2114	The role of bromodomain proteins in regulating gene expression. 2012 , 3, 320-43	78
2113	Perspectives on the discovery of small-molecule modulators for epigenetic processes. 2012 , 17, 555-71	21
2112	Bioinformatics and variability in drug response: a protein structural perspective. 2012 , 9, 1409-37	57
2111	Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. 2012 , 55, 587-96	158
2110	Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. 2012 , 55, 576-86	162
2109	Chromatin as an expansive canvas for chemical biology. 2012 , 8, 417-27	96
2108	Epigenetic protein families: a new frontier for drug discovery. 2012 , 11, 384-400	1003
2107	Suppression of the antiviral response by an influenza histone mimic. <i>Nature</i> , 2012 , 483, 428-33	50.4 216
2106	BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. 2012 , 92, 1147-54	194
2105	Quantitative imaging with fluorescent biosensors. 2012 , 63, 663-706	177
2104	The Global Cancer Genomics Consortium: interfacing genomics and cancer medicine. 2012 , 72, 3720-4	6
2103	Epigenetic mechanisms in neurological disease. 2012 , 18, 1194-204	328

2102	Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. 2012 , 55, 7346-59	224
2101	Menin as a hub controlling mixed lineage leukemia. 2012 , 34, 771-80	24
2100	Protein-protein interaction inhibitors get into the groove. 2012 , 11, 173-5	199
2099	Pathogenesis of human B cell lymphomas. 2012 , 30, 565-610	307
2098	Cancer genetics and epigenetics: two sides of the same coin?. 2012 , 22, 9-20	784
2097	Mass spectrometry-based proteomics in preclinical drug discovery. 2012 , 19, 72-84	125
2096	What makes a good drug target?. 2012 , 17 Suppl, S24-30	69
2095	Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. 2012 , 20, 1878-86	90
2094	Development of live-cell imaging probes for monitoring histone modifications. 2012 , 20, 1887-92	17
2093	The role of chromatin in Plasmodium gene expression. 2012 , 14, 819-28	28
2092	Histone regulation in the CNS: basic principles of epigenetic plasticity. 2013 , 38, 3-22	103
2091	HIV-1 transcription and latency: an update. 2013 , 10, 67	218
2090	The BET protein FSH functionally interacts with ASH1 to orchestrate global gene activity in Drosophila. 2013 , 14, R18	22
2089	A quantitative atlas of histone modification signatures from human cancer cells. 2013 , 6, 20	99
2088	Mechanisms of mixed-lineage leukemia. 2013 , 2, 207-217	10
2087	The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. 2013 , 4, 140-144	58
2086	The importance of diagnosing NUT midline carcinoma. 2013 , 7, 11-6	80
2085	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. 2013 , 63, 175-9	118

2084	Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. 2013 , 183, 470-9	85
2083	Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. 2013 , 4, 835-40	88
2082	Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. 2013 , 17, 369-78	20
2081	Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas. 2013 , 13, 983-96	6
2080	Integrative avenues for exploring the dynamics and evolution of protein interaction networks. 2013 , 24, 775-83	13
2079	Mechanism and Kinetics of Acetyl-Lysine Binding to Bromodomains. 2013 , 9, 4225-32	24
2078	Inflammatory breast cancer (IBC): clues for targeted therapies. 2013 , 140, 23-33	59
2077	Obesity, Inflammation and Cancer. 2013 ,	4
2076	Development of neurodevelopmental disorders: a regulatory mechanism involving bromodomain-containing proteins. 2013 , 5, 4	10
2075	Structural conservation of distinctive N-terminal acetylation-dependent interactions across a family of mammalian NEDD8 ligation enzymes. 2013 , 21, 42-53	72
2074	Logic of the inflammation-associated transcriptional response. 2013 , 119, 107-33	5
2073	WHSC1 links transcription elongation to HIRA-mediated histone H3.3 deposition. 2013 , 32, 2392-406	44
2072	Does bromodomain flexibility influence histone recognition?. 2013 , 587, 2158-63	33
2071	Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. 2013 , 14, 765-80	286
2070	Epigenetic alterations in acute kidney injury. 2013 , 33, 327-40	35
2069	Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma. 2013 , 5, 397-415	11
2068	Chromatin proteins and modifications as drug targets. <i>Nature</i> , 2013 , 502, 480-8	50.4 345
2067	Local cAMP signaling in disease at a glance. 2013 , 126, 4537-43	53

2066	Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. 2013 , 155, 1581-1595	250
2065	New strategies in the treatment of multiple myeloma. 2013 , 19, 3337-44	104
2064	The epigenetics of epithelial-mesenchymal plasticity in cancer. 2013 , 19, 1438-49	851
2063	Tudor: a versatile family of histone methylation 'readers'. 2013 , 38, 546-55	104
2062	Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. 2013 , 24, 777-90	491
2061	Developing epigenetic diagnostics and therapeutics for brain disorders. 2013 , 19, 732-41	19
2060	Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. 2013 , 27, 2341-50	85
2059	Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. 2013 , 56, 7501-15	225
2058	Environmental Epigenomics in Health and Disease. 2013 ,	1
2057	Environmental Impact on Epigenetic Histone Language. 2013 , 163-187	
2056	Recent Advances in Small-Molecule Modulation of Epigenetic Targets. 2013 , 185-203	7
2055	Targeting Protein-Protein Interactions to Treat Cancer: Recent Progress and Future Directions. 2013 , 48, 227-245	8
2054	The chromatin scaffold protein SAFB1 renders chromatin permissive for DNA damage signaling. 2013 , 52, 206-20	50
2053	BET bromodomains mediate transcriptional pause release in heart failure. 2013 , 154, 569-82	277
2052	Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. 2013 , 5, 1180-95	52
2051	Why is epigenetics important in understanding the pathogenesis of inflammatory musculoskeletal diseases?. 2013 , 15, 209	18
2050	ICBS2012 catalyzes robust response from global chemical biology community. 2013 , 8, 12-8	2
2049	Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κ B (NF- κ B) signaling. 2013 , 288, 36094-105	30

2048	Proteomics in epigenetics: new perspectives for cancer research. 2013 , 12, 205-18	26
2047	Objective assessment of cancer genes for drug discovery. 2013 , 12, 35-50	89
2046	Target identification of small molecules based on chemical biology approaches. 2013 , 9, 897-914	62
2045	Protein arginine methyltransferases and cancer. 2013 , 13, 37-50	645
2044	Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition. 2013 , 138, 1-17	96
2043	Isothermal titration calorimetry vs. high performance liquid chromatography fingerprint. 2013 , 111, 965-970	
2042	Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. 2013 , 9, 184-91	129
2041	BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. 2013 , 190, 3670-8	283
2040	Tipping the lysine methylation balance in disease. 2013 , 99, 127-35	31
2039	Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers. 2013 , 5, 302-13	24
2038	BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. 2013 , 73, 6264-76	161
2037	The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites. 2013 , 5, 886-94	117
2036	Malignant genome reprogramming by ATAD2. 2013 , 1829, 1010-4	56
2035	Perspectives on natural product epigenetic modulators in chemical biology and medicine. 2013 , 30, 605-24	40
2034	Target validation using chemical probes. 2013 , 9, 195-9	297
2033	Small-molecular modulators of cancer-associated epigenetic mechanisms. 2013 , 9, 873-96	39
2032	Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. 2013 , 12, 88-97	38
2031	Interplay between the cancer genome and epigenome. 2013 , 153, 38-55	588

2030	Selective inhibition of tumor oncogenes by disruption of super-enhancers. 2013 , 153, 320-34	1744
2029	Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. 2013 , 6, 223-32	30
2028	Oxidants, antioxidants and the current incurability of metastatic cancers. 2013 , 3, 120144	257
2027	Mechanisms of epigenetic regulation of leukemia onset and progression. 2013 , 117, 1-38	20
2026	Targeting HIV latency: pharmacologic strategies toward eradication. 2013 , 18, 541-51	115
2025	Role and potential for therapeutic targeting of MYB in leukemia. 2013 , 27, 269-77	78
2024	iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. 2013 , 18, 958-68	79
2023	Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation. 2013 , 118, 37-128	51
2022	Targeting protein-protein interactions as an anticancer strategy. 2013 , 34, 393-400	230
2021	Energetically unfavorable amide conformations for N6-acetyllysine side chains in refined protein structures. 2013 , 81, 1051-7	9
2020	The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. 2013 , 153, 1552-66	224
2019	Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. 2013 , 56, 3217-27	106
2018	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. 2013 , 13, 486-96	44
2017	Recent developments in human immunodeficiency virus-1 latency research. 2013 , 94, 917-932	14
2016	Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. 2013 , 56, 3833-51	99
2015	Innovation in academic chemical screening: filling the gaps in chemical biology. 2013 , 17, 329-38	18
2014	The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. <i>Nature</i> , 2013 , 498, 246-50	50.4 214
2013	Readout of epigenetic modifications. 2013 , 82, 81-118	242

2012	Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. 2013 , 8, 2360-5	113
2011	The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. 2013 , 41, 277-87	206
2010	Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. 2013 , 56, 9251-64	96
2009	Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. 2013 , 97, 198-209	12
2008	The making of I-BET762, a BET bromodomain inhibitor now in clinical development. 2013 , 56, 7498-500	65
2007	Improved assays for determining the cytosolic access of peptides, proteins, and their mimetics. 2013 , 52, 9036-46	35
2006	Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. 2013 , 56, 8073-88	100
2005	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. 2013 , 56, 10183-7	85
2004	PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. 2013 , 73, 3336-46	191
2003	O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. 2013 , 73, 5277-87	191
2002	The "histone mimicry" by pathogens. 2013 , 78, 81-90	8
2001	Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. 2013 , 19, 578-613	64
2000	Maintenance of muscle myosin levels in adult <i>C. elegans</i> requires both the double bromodomain protein BET-1 and sumoylation. 2013 , 2, 1354-63	5
1999	Targeting MYCN: a good BET for improving neuroblastoma therapy?. 2013 , 3, 255-7	13
1998	Drug discovery in academic institutions. 2013 , 2013, 300-5	2
1997	Reactivation of latent HIV: do all roads go through P-TEFb?. 2013 , 8,	21
1996	The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. 2013 , 102, 293-326	47
1995	Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. 2013 , 91, 49-75	28

1994	Targeted drug discovery for pediatric leukemia. 2013 , 3, 170	15
1993	Bromodomain proteins in HIV infection. 2013 , 5, 1571-86	31
1992	Brd4 is displaced from HPV replication factories as they expand and amplify viral DNA. 2013 , 9, e1003777	53
1991	A chromatin link to caste identity in the carpenter ant <i>Camponotus floridanus</i> . 2013 , 23, 486-96	104
1990	Chromatin targeting drugs in cancer and immunity. 2013 , 27, 1731-8	22
1989	Current understanding of the role of the Brd4 protein in the papillomavirus lifecycle. 2013 , 5, 1374-94	33
1988	Exploring the <i>Trypanosoma brucei</i> Hsp83 potential as a target for structure guided drug design. 2013 , 7, e2492	25
1987	Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. 2013 , 27, 2648-62	300
1986	BMPs morph into new roles in ovarian cancer. 2013 , 12, 389	3
1985	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. 2013 , 12, 452-62	169
1984	Wip1 regulation: who controls a reset button?. 2013 , 12, 390	
1983	BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. 2013 , 83, 283-93	50
1982	Wip1 downregulation conserves truncated DNA damage response (DDR) in mitosis. 2013 , 12, 391	3
1981	The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy. 2013 , 27, 1299-312	56
1980	New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization. 2013 , 3, 1099-102	11
1979	BET bromodomain inhibition suppresses TH17-mediated pathology. 2013 , 210, 2181-90	178
1978	Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. 2013 , 3, a014258	34
1977	BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. 2013 , 33, 2497-507	122

1976	Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. 2013 , 87, 12721-36	102
1975	Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. 2013 , 83, 563-76	27
1974	Uncoupling Obesity from Cancer: Bromodomain Co-regulators That Control Inflammatory Networks. 2013 , 61-81	3
1973	RETHINKING EPISTEMIC INCENTIVES: HOW PATIENT-CENTERED, OPEN SOURCE DRUG DISCOVERY GENERATES MORE VALUABLE KNOWLEDGE SOONER. 2013 , 10, 417-439	
1972	Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain. 2013 , 69, 2161-4	18
1971	Inhibition of BET bromodomain targets genetically diverse glioblastoma. 2013 , 19, 1748-59	223
1970	Metabolic regulation of osteoclast differentiation and function. 2013 , 28, 2392-9	122
1969	Small-molecule modulators for epigenetics targets. 2013 , 8, 1885-91	19
1968	Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. 2013 , 19, 6183-92	150
1967	Targeting MYCN in neuroblastoma by BET bromodomain inhibition. 2013 , 3, 308-23	460
1966	Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma. 2013 , 5, 1149-50	
1965	Bromodomains as therapeutic targets in cancer. 2013 , 12, 219-30	58
1964	Bromodomains on the brain. 2013 , 6, 277-277	
1963	Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. 2013 , 27, 1974-85	134
1962	BETting on Th17 cells. 2013 , 6, 1246-1246	
1961	BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. 2013 , 3, e126	69
1960	Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. 2013 , 32, 4664-74	32
1959	Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. 2013 , 87, 3871-84	59

1958	Role of MYC in Medulloblastoma. 2013 , 3,	93
1957	Epe1 recruits BET family bromodomain protein Bdf2 to establish heterochromatin boundaries. 2013 , 27, 1886-902	43
1956	RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. 2013 , 110, 19754-9	305
1955	Two faces of brd4: mitotic bookmark and transcriptional lynchpin. 2013 , 4, 13-7	65
1954	BET proteins promote efficient murine leukemia virus integration at transcription start sites. 2013 , 110, 12036-41	143
1953	P-TEFb as a target to reactivate latent HIV: two Brds are now in hand. 2013 , 12, 392-3	8
1952	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. 2013 , 98, 1689-96	9
1951	Stimulation of Hepatic Apolipoprotein A-I Production by Novel Thieno-Triazolodiazepines: Roles of the Classical Benzodiazepine Receptor, PAF Receptor, and Bromodomain Binding. 2013 , 6, 47-54	13
1950	4-Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading. 2013 , 125, 14305-14309	6
1949	Preparation of Small-Molecule Microarrays by trans-Cyclooctene Tetrazine Ligation and Their Application in the High-Throughput Screening of Protein-Protein Interaction Inhibitors of Bromodomains. 2013 , 125, 14310-14314	9
1948	Preparation of small-molecule microarrays by trans-cyclooctene tetrazine ligation and their application in the high-throughput screening of protein-protein interaction inhibitors of bromodomains. 2013 , 52, 14060-4	36
1947	NUT midline carcinoma: an aggressive intrathoracic neoplasm. 2013 , 8, 1335-8	32
1946	Basic science: Epigenetic programming and the respiratory system. 2013 , 9, 278-288	3
1945	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. 2013 , 52, 14055-9	90
1944	Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. 2013 , 8, e54873	56
1943	BRD4 short isoform interacts with RRP1B, SIPA1 and components of the LINC complex at the inner face of the nuclear membrane. 2013 , 8, e80746	39
1942	RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. 2013 , 8, e83190	135
1941	Alterations in brain-derived neurotrophic factor in the mouse hippocampus following acute but not repeated benzodiazepine treatment. 2013 , 8, e84806	19

1940	A case of NUT midline carcinoma with no HPV infection, slight EWSR1 rearrangement and strong expression of EGFR. 2013 , 99, e152-e155	3
1939	Acute lymphoblastic leukemia (ALL). 777-785	
1938	Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells. 2014 , 9, e95051	70
1937	Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells. 2014 , 3, e04631	53
1936	Fragment-based drug discovery and protein-protein interactions. 2014 , 13	12
1935	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. 2014 , 5, 2355-71	80
1934	Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. 2014 , 6, 473-84	46
1933	Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression. 2014 , 9, 634-43	21
1932	BETting on a new prostate cancer treatment. 2014 , 13, 2015-6	3
1931	Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. 2014 , 6, 179-204	27
1930	BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer. 2014 , 15, 1583-5	21
1929	The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. 2014 , 95, 451-60	35
1928	BET bromodomain proteins are required for glioblastoma cell proliferation. 2014 , 9, 611-20	100
1927	Molecular mechanisms of retroviral integration site selection. 2014 , 42, 10209-25	82
1926	Oncogenic mechanisms in Burkitt lymphoma. 2014 , 4,	143
1925	Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays. 2014 , 9, 1393-404	33
1924	Novel methods and approaches to acute lymphoblastic leukemia drug discovery. 2014 , 9, 1435-46	7
1923	Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. 2014 , 34, 1059-69	12

1922	Cancer stem cells as a target population for drug discovery. 2014 , 6, 1567-85	7
1921	The histone deacetylase Hdac1 regulates inflammatory signalling in intestinal epithelial cells. 2014 , 11, 43	15
1920	References. 2014 , 167-204	
1919	What is the future of bromodomains in targeted drug development?. 2014 , 6, 1101-3	
1918	Synthetic lethal screens as a means to understand and treat MYC-driven cancers. 2014 , 4,	56
1917	MYC activation is a hallmark of cancer initiation and maintenance. 2014 , 4,	430
1916	Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes. 2014 , 42, 4868-81	31
1915	Epigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins. 2014 , 121-144	
1914	Chromatin's rising tide. 2014 , 7, 545-545	1
1913	Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. 2014 , 28, 1819-27	43
1912	The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. 2014 , 5, e1450	46
1911	The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. 2014 , 5, e1195	74
1910	The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. 2014 , 134, 2795-2805	50
1909	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. 2014 , 123, 1040-50	115
1908	Expanding into new (bromo)domains. 2014 , 7, 420-420	
1907	Comparative drug screening in NUT midline carcinoma. 2014 , 110, 1189-98	29
1906	BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. 2014 , 111, E2721-30	163
1905	NUT midline carcinomas in the thymic region. 2014 , 27, 1649-56	8

1904	Epigenetic control of gene function in schistosomes: a source of therapeutic targets?. 2014 , 5, 317	28
1903	The cellular bromodomain protein Brd4 has multiple functions in E2-mediated papillomavirus transcription activation. 2014 , 6, 3228-49	29
1902	Attempt at a systemic outlook on aging and carcinogenesis. 2014 , 10,	0
1901	Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. 2014 , 16, 757-69	37
1900	A loss of function screen of identified genome-wide association study Loci reveals new genes controlling hematopoiesis. 2014 , 10, e1004450	18
1899	New Approaches to Target T-ALL. 2014 , 4, 170	39
1898	Targeting the BET family for the treatment of leukemia. 2014 , 6, 153-5	6
1897	Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. 2014 , 8, 1919-1929	119
1896	Understanding susceptibility to breast cancer metastasis: the genetic approach. 2014 , 3, 165-172	6
1895	Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. 2014 , 171, 4981-5010	21
1894	Therapeutic strategies to inhibit MYC. 2014 , 4,	143
1893	Fluorinated aromatic amino acids are sensitive ^{19}F NMR probes for bromodomain-ligand interactions. 2014 , 9, 2755-60	64
1892	Epigenetic Therapy of Cancer. 2014 ,	
1891	Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokines. 2014 , 66, 1537-46	24
1890	Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. 2014 , 5, 1871-1878	10
1889	Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. 2014 , 289, 9304-19	96
1888	Inactivation of MYC reverses tumorigenesis. 2014 , 276, 52-60	34
1887	Minireview: Conversing with chromatin: the language of nuclear receptors. 2014 , 28, 3-15	12

1886	Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. 2014 , 26, 909-922	294
1885	BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos. 2014 , 21, 1950-60	45
1884	The bromodomain of Gcn5 regulates site specificity of lysine acetylation on histone H3. 2014 , 13, 2896-910	50
1883	ARID1B is a specific vulnerability in ARID1A-mutant cancers. 2014 , 20, 251-4	243
1882	Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. 2014 , 6, a018663	49
1881	Epigenetics in the hematologic malignancies. 2014 , 99, 1772-83	48
1880	Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. 2014 , 34, 1136-44	136
1879	The myc 3' wnt-responsive element suppresses colonic tumorigenesis. 2014 , 34, 1659-69	8
1878	The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. 2014 , 289, 35494-502	78
1877	Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. 2014 , 13, 1194-205	56
1876	Sustaining cancer through addictive ectopic gene activation. 2014 , 26, 73-7	15
1875	Chromatin-regulating proteins as targets for cancer therapy. 2014 , 55, 613-28	25
1874	Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. 2014 , 42, 7577-90	128
1873	Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma. 2014 , 74, 3332-43	39
1872	Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. 2014 , 9, 234-247	144
1871	BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. 2014 , 74, 7090-102	60
1870	DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. 2014 , 9, 1841-1855	183
1869	Pleiotrophin antagonizes Brd2 during neuronal differentiation. 2014 , 127, 2554-64	21

1868	BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. 2014 , 13, 1907-17	74
1867	Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes. 2014 , 6, 265ra169	65
1866	Role of transcription factor acetylation in diabetic kidney disease. 2014 , 63, 2440-53	139
1865	Systems Analysis of Chromatin-Related Protein Complexes in Cancer. 2014 ,	
1864	Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses. 2014 , 15, 244-7	9
1863	BET-ting on chromatin-based therapeutics for heart failure. 2014 , 74, 98-102	33
1862	Privileged diazepam compounds and their emergence as bromodomain inhibitors. 2014 , 21, 573-83	49
1861	Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics. 2014 , 264, 171-85	36
1860	Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. 2014 , 33, 2928-37	75
1859	Epigenetic drugs that do not target enzyme activity. 2014 , 12, e29-34	3
1858	Structured water molecules in the binding site of bromodomains can be displaced by cosolvent. 2014 , 9, 573-9	37
1857	Nuclear Signaling Pathways and Targeting Transcription in Cancer. 2014 ,	3
1856	Naphthyridines as novel BET family bromodomain inhibitors. 2014 , 9, 580-9	28
1855	Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. 2014 , 34, 415-27	54
1854	Exploiting epigenetic vulnerabilities for cancer therapeutics. 2014 , 35, 136-45	48
1853	A novel microscopy-based high-throughput screening method to identify proteins that regulate global histone modification levels. 2014 , 19, 287-96	5
1852	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. 2014 , 46, 364-70	263
1851	Drug discovery: follow your lead. 2014 , 10, 244-5	9

1850	Targeting tumour-supportive cellular machineries in anticancer drug development. 2014 , 13, 179-96	169
1849	Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. 2014 , 10, 305-12	251
1848	Comprehensive molecular characterization of urothelial bladder carcinoma. <i>Nature</i> , 2014 , 507, 315-22	50.4 1963
1847	Bromodomains and their pharmacological inhibitors. 2014 , 9, 438-64	92
1846	Chromatin contributions to the regulation of innate immunity. 2014 , 32, 489-511	119
1845	Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. 2014 , 28, 1396-406	60
1844	Targeting bromodomains: epigenetic readers of lysine acetylation. 2014 , 13, 337-56	880
1843	Binding of the histone chaperone ASF1 to the CBP bromodomain promotes histone acetylation. 2014 , 111, E1072-81	41
1842	BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction. 2014 , 93, 657-62	99
1841	Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression. 2014 , 356, 617-30	7
1840	Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. 2014 , 5, 3511	102
1839	A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation- π interaction. 2014 , 53, 6126-30	94
1838	Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. 2014 , 24, 2493-6	53
1837	A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation- π Interaction. 2014 , 126, 6240-6244	11
1836	Genome-wide localization of small molecules. 2014 , 32, 92-6	138
1835	Design of small molecule epigenetic modulators. 2014 , 24, 21-32	26
1834	NUT midline carcinoma. 2014 , 14, 149-50	91
1833	Cause and consequence of cancer/testis antigen activation in cancer. 2014 , 54, 251-72	149

1832	Targeting protein-protein interaction by small molecules. 2014 , 54, 435-56	133
1831	p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. 2014 , 74, 1870-1880	59
1830	Development of anticancer drugs based on the hallmarks of tumor cells. 2014 , 35, 3981-95	24
1829	[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. 2014 , 57, 462-76	75
1828	Innate immunity. A Spaetzle-like role for nerve growth factor β in vertebrate immunity to <i>Staphylococcus aureus</i> . 2014 , 346, 641-646	55
1827	Biased multicomponent reactions to develop novel bromodomain inhibitors. 2014 , 57, 9019-27	67
1826	Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. 2014 , 346, 638-641	108
1825	Epigenetic Changes in Gliomas. 2014 , 23-45	
1824	A tale of chromatin and transcription in 100 structures. 2014 , 159, 985-994	21
1823	Stabilization of protein-protein interactions by small molecules. 2014 , 19, 1812-1821	38
1822	Targeting components of epigenome by small molecules. 2014 , 37, 1367-74	9
1821	Chemical Diagnostics. 2014 ,	2
1820	PRC2 loss amplifies Ras signaling in cancer. 2014 , 46, 1154-5	15
1819	Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger. 2014 , 9, 2864-74	45
1818	BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. 2014 , 21, 1047-57	185
1817	AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. 2014 , 159, 558-71	229
1816	Epigenetic mechanisms in heart failure pathogenesis. 2014 , 7, 850-863	22
1815	SPRTN is a new player in an old story. 2014 , 46, 1155-7	6

1814	Discovery of BET bromodomain inhibitors and their role in target validation. 2014 , 5, 288-296	31
1813	Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain. 2014 , 5, 1843-1848	41
1812	Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. 2014 , 111, 11365-70	127
1811	"Minimalist" cyclopropene-containing photo-cross-linkers suitable for live-cell imaging and affinity-based protein labeling. 2014 , 136, 9990-8	131
1810	Unravelling the genomic targets of small molecules using high-throughput sequencing. 2014 , 15, 783-96	71
1809	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. 2014 , 346, 1373-7	484
1808	Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. 2014 , 5, 5418	78
1807	NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. 2014 , 4, 928-41	141
1806	Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking. 2014 , 53, 6706-16	18
1805	Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography. 2014 , 5, 540-546	38
1804	Chemical synthesis of the ATAD2 bromodomain. 2014 , 111, 2891-6	17
1803	Molecular Dynamics Simulations of Bromodomains Reveal Binding-Site Flexibility and Multiple Binding Modes of the Natural Ligand Acetyl-Lysine. 2014 , 54, 1084-1092	14
1802	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. 2014 , 5, 1190-5	64
1801	RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. 2014 , 4, 318-33	65
1800	Chemical biology approaches to target validation in cancer. 2014 , 17, 87-100	30
1799	Development and classes of epigenetic drugs for cancer. 2014 , 455, 58-69	65
1798	NF- κ B directs dynamic super enhancer formation in inflammation and atherogenesis. 2014 , 56, 219-231	392
1797	Eusocial insects as emerging models for behavioural epigenetics. 2014 , 15, 677-88	133

1796	Identification of small molecule modulators of gene transcription with anticancer activity. 2014 , 9, 2603-11	4
1795	The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. 2014 , 57, 8111-31	122
1794	MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. 2014 , 1846, 457-67	33
1793	Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. 2014 , 9, 1160-71	164
1792	Demystifying NUT midline carcinoma: radiologic and pathologic correlations of an aggressive malignancy. 2014 , 203, W391-9	25
1791	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. 2014 , 13, 1142-54	143
1790	Chromatin reader Brd4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining. 2014 , 55, 97-110	54
1789	Non-small-cell lung cancers: a heterogeneous set of diseases. 2014 , 14, 535-46	934
1788	The growing landscape of lysine acetylation links metabolism and cell signalling. 2014 , 15, 536-50	857
1787	Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. 2014 , 136, 9308-19	198
1786	Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers. 2014 , 462, 397-413	16
1785	Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7). 2014 , 57, 2874-83	82
1784	The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. 2014 , 9, 495-502	85
1783	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. 2014 , 13, 673-91	1028
1782	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. <i>Nature</i> , 2014 , 514, 247-51	50.4 313
1781	Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. 2014 , 21, 841-854	99
1780	7,9-Diaryl-1,6,8-trioxaspiro[4.5]dec-3-en-2-ones: readily accessible and highly potent anticancer compounds. 2014 , 24, 4035-8	3
1779	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014 , 510, 278-82	50.4 650

1778	Somatic alterations and dysregulation of epigenetic modifiers in cancers. 2014 , 455, 24-34	25
1777	SEC-TID: A Label-Free Method for Small-Molecule Target Identification. 2014 , 19, 917-27	16
1776	BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. 2014 , 13, 2315-27	110
1775	Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia. 2014 , 74, 7048-59	36
1774	Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. 2014 , 7, 14	58
1773	Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. 2014 , 21, 1102-14	699
1772	Epigenetic drugs against cancer: an evolving landscape. 2014 , 88, 1651-68	37
1771	Small molecule control of chromatin remodeling. 2014 , 21, 1196-210	45
1770	Challenges in developing novel DNA methyltransferases inhibitors for cancer therapy. 2014 , 6, 1237-40	10
1769	Cancer genomics identifies disrupted epigenetic genes. 2014 , 133, 713-25	41
1768	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. 2014 , 123, 697-705	152
1767	Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. 2014 , 8, 460-9	115
1766	The discovery of first-in-class drugs: origins and evolution. 2014 , 13, 577-87	308
1765	Phenotypic screening in cancer drug discovery - past, present and future. 2014 , 13, 588-602	307
1764	Mechanism and factors that control HIV-1 transcription and latency activation. 2014 , 15, 455-65	9
1763	JARID1B is a luminal lineage-driving oncogene in breast cancer. 2014 , 25, 762-77	131
1762	Bromodomains: pockets with therapeutic potential. 2014 , 20, 477-8	19
1761	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. 2014 , 20, 732-40	213

1760	Hot spots in protein-protein interfaces: towards drug discovery. 2014 , 116, 165-73	101
1759	Trypanosoma cruzi bromodomain factor 3 binds acetylated β -tubulin and concentrates in the flagellum during metacyclogenesis. 2014 , 13, 822-31	19
1758	High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. 2014 , 13, 89	88
1757	The basal transcription machinery as a target for cancer therapy. 2014 , 14, 18	39
1756	Epigenetic modulators from "The Big Blue": a treasure to fight against cancer. 2014 , 351, 182-97	30
1755	Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression. 2014 , 192, 4913-4920	41
1754	Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. 2014 , 9, 2274-2285	24
1753	Writers and readers of histone acetylation: structure, mechanism, and inhibition. 2014 , 6, a018762	287
1752	Vulnerabilities of mutant SWI/SNF complexes in cancer. 2014 , 26, 309-317	171
1751	Drugging MYCN through an allosteric transition in Aurora kinase A. 2014 , 26, 414-427	179
1750	Selective Targeting of Protein Interactions Mediated by BET Bromodomains. 2014 , 295-308	2
1749	BETs abet Tam-R in ER-positive breast cancer. 2014 , 24, 899-900	9
1748	From fly wings to targeted cancer therapies: a centennial for notch signaling. 2014 , 25, 318-34	240
1747	Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. 2014 , 23, 1321-32	6
1746	A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. 2014 , 13, 1492-502	41
1745	Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. 2014 , 426, 1661-76	47
1744	BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. 2014 , 6, 81-92	56
1743	A rare Japanese case with a NUT midline carcinoma in the nasal cavity: a case report with immunohistochemical and genetic analyses. 2014 , 210, 383-8	12

1742	The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. 2014 , 7, 1009-19	24
1741	Identification of a BET family bromodomain/casein kinase II/TAF-containing complex as a regulator of mitotic condensin function. 2014 , 6, 892-905	9
1740	Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma. 2014 , 103, 189-203	39
1739	The bromodomain: from epigenome reader to druggable target. 2014 , 1839, 676-85	131
1738	Male contraception: another Holy Grail. 2014 , 24, 419-24	25
1737	Biochemie und Molekularbiologie 2013. 2014 , 62, 302-312	
1736	Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. 2014 , 10, 2384-97	31
1735	The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes. 2014 , 5, 342-351	52
1734	The mechanisms behind the therapeutic activity of BET bromodomain inhibition. 2014 , 54, 728-36	548
1733	Pharmacological inhibition of bromodomain-containing proteins in inflammation. 2014 , 6,	14
1732	Epigenetic control of immunity. 2014 , 6,	75
1731	I-BET151 selectively regulates IL-6 production. 2014 , 1842, 1549-55	31
1730	BET bromodomain inhibitors: a patent review. 2014 , 24, 185-99	91
1729	Control of NF- κ B activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. 2014 , 27, 1126-37	67
1728	A rationale to target the SWI/SNF complex for cancer therapy. 2014 , 30, 356-63	131
1727	Structural insights into acetylated-histone H4 recognition by the bromodomain-PHD finger module of human transcriptional coactivator CBP. 2014 , 22, 353-60	36
1726	Brd4 maintains constitutively active NF- κ B in cancer cells by binding to acetylated RelA. 2014 , 33, 2395-404	173
1725	MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. 2014 , 33, 1736-1742	121

1724	Harnessing the potential of epigenetic therapy to target solid tumors. 2014 , 124, 56-63	106
1723	10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells. 2014 , 8, 1355-1359	11
1722	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. 2014 , 124, 3577-82	40
1721	Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia. 2014 , 3, 379-381	0
1720	A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel. 2014 , 36, e476-80	14
1719	Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery. 2015 , 13, 1444-1455	97
1718	BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. 2015 , 2, 1650-61	40
1717	Epigenome-modifying tools in asthma. 2015 , 7, 1017-32	39
1716	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. 2015 , 136, 2055-64	79
1715	Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. 2015 , 10, 951-9	68
1714	A Bead-Based Proximity Assay for BRD4 Ligand Discovery. 2015 , 7, 263-278	17
1713	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. 2015 , 126, 1565-74	76
1712	Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. 2015 , 125, 346-57	148
1711	Therapeutic targeting of BET protein BRD4 delays murine lupus. 2015 , 29, 314-319	15
1710	Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. 2015 , 5, 16924	40
1709	Dual transcriptome sequencing reveals resistance of TLR4 ligand-activated bone marrow-derived macrophages to inflammation mediated by the BET inhibitor JQ1. 2015 , 5, 16932	19
1708	Improving protein-ligand binding site prediction accuracy by classification of inner pocket points using local features. 2015 , 7, 12	19
1707	Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition. 2015 , 74, 778-90	47

1706	Multiple Structural Clustering of Bromodomains of the Bromo and Extra Terminal (BET) Proteins Highlights Subtle Differences in Their Structural Dynamics and Acetylated Leucine Binding Pocket. 2015 , 51, 735-744	5
1705	Identifizierung von niedermolekularen kovalenten Bromodomäne-Bindern aus einer DNA-kodierten Bibliothek. 2015 , 127, 6155-6159	12
1704	Dioxygen Binding in the Active Site of Histone Demethylase JMJD2A and the Role of the Protein Environment. 2015 , 21, 18983-92	16
1703	Histone deacetylase inhibitor for NUT midline carcinoma. 2015 , 62, 715-7	45
1702	An Atypical Case of Microphthalmos With Cyst: Cyst Masquerading as Phthisical Eye. 2015 , 31, e150-2	2
1701	Unlocking the potential of chemical probes for methyl-lysine reader proteins. 2015 , 7, 1831-3	4
1700	Orbital Involvement by NUT Midline Carcinoma. 2015 , 31, e147-50	8
1699	Redesign of a Fluorogenic Labeling System To Improve Surface Charge, Brightness, and Binding Kinetics for Imaging the Functional Localization of Bromodomains. 2015 , 127, 14576-14579	9
1698	Redesign of a Fluorogenic Labeling System To Improve Surface Charge, Brightness, and Binding Kinetics for Imaging the Functional Localization of Bromodomains. 2015 , 54, 14368-71	25
1697	Partners in crime: The role of tandem modules in gene transcription. 2015 , 24, 1347-59	7
1696	The Role of Hedgehog Signaling in Tumor Induced Bone Disease. 2015 , 7, 1658-83	17
1695	MYC as therapeutic target in leukemia and lymphoma. 2015 , 75	2
1694	Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. 2015 , 6, 5501-16	162
1693	Open access target validation is a more efficient way to accelerate drug discovery. 2015 , 13, e1002164	16
1692	Molecular Docking Study Characterization of Rare Flavonoids at the Nac-Binding Site of the First Bromodomain of BRD4 (BRD4 BD1). 2015 , 2015, 1-15	17
1691	DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. 2015 , 348, 1376-81	884
1690	Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. 2015 , 10, 1770-7	504
1689	Progress and challenges in the use of latent HIV-1 reactivating agents. 2015 , 36, 908-16	30

1688	The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. 2015 , 5, e313	58
1687	GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. 2015 , 5, 9489	68
1686	Scalable syntheses of the BET bromodomain inhibitor JQ1. 2015 , 56, 3354-3457	9
1685	MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. 2015 , 5, 636-51	52
1684	Histone Recognition. 2015 ,	2
1683	The State of the Art of Epigenetic Technologies. 2015 , 1-18	1
1682	Animal Model Study of Epigenetic Inhibitors. 2015 , 447-477	
1681	The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis. 2015 , 78, 114-21	23
1680	A Plasmodium Falciparum Bromodomain Protein Regulates Invasion Gene Expression. 2015 , 17, 741-51	74
1679	Small-Molecule Modulation of Methyl-Lysine-Mediated Interactions. 2015 , 243-271	2
1678	Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. 2015 , 59, 75-88	128
1677	Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. 2015 , 27, 837-51	172
1676	Identification of Covalent Bromodomain Binders through DNA Display of Small Molecules. 2015 , 54, 6057-61	46
1675	MLL leukemia and future treatment strategies. 2015 , 348, 221-8	18
1674	BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. 2015 , 5, 10120	87
1673	Alternative modulation of protein-protein interactions by small molecules. 2015 , 35, 78-85	62
1672	Functions of BET proteins in erythroid gene expression. 2015 , 125, 2825-34	70
1671	Enhancer-associated RNAs as therapeutic targets. 2015 , 15, 723-34	19

1670	Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. 2015 , 93, 149-57	14
1669	Novel approaches to pediatric leukemia treatment. 2015 , 15, 811-28	2
1668	BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses. 2015 , 16, 1997-2001	15
1667	Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities. 2015 , 22, 1588-96	38
1666	Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies. 2015 , 6, e2014	14
1665	NUT expression in primary lung tumours. 2015 , 10, 156	5
1664	BRD4 is a novel therapeutic target for liver fibrosis. 2015 , 112, 15713-8	126
1663	Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. 2015 , 1, e1500723	76
1662	Harnessing the crowd to accelerate molecular medicine research. 2015 , 21, 403-5	6
1661	Suppression of interferon γ gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. 2015 , 468, 363-72	8
1660	BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF- κ B pathway. 2015 , 10, 2319-2324	45
1659	Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer. 2015 , 80, 249-55	9
1658	50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. 2015 , 16, 258-64	480
1657	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. 2015 , 112, 232-7	112
1656	NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review. 2015 , 211, 92-8	16
1655	BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF- κ B activation. 2015 , 294, 1-8	9
1654	Neuroepigenomics: Resources, Obstacles, and Opportunities. 2015 , 1, 2-13	14
1653	The biology of castration-resistant prostate cancer. 2015 , 39, 17-28	18

1652	Epstein-Barr virus oncoprotein super-enhancers control B cell growth. 2015 , 17, 205-16	108
1651	Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. 2015 , 352, 579-89	46
1650	Reprint of: B cells in chronic graft-versus-host disease. 2015 , 21, S11-8	4
1649	Retrospective analysis of nuclear protein in testis (NUT) midline carcinoma in the upper aerodigestive tract and mediastinum. 2015 , 119, 213-20	17
1648	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. 2015 , 16, 280-96	150
1647	Defining the orphan functions of lysine acetyltransferases. 2015 , 10, 85-94	36
1646	Characterization of BRD4 during mammalian postmeiotic sperm development. 2015 , 35, 1433-48	29
1645	Chemogenomic profiling of endogenous PARK2 expression using a genome-edited coincidence reporter. 2015 , 10, 1188-97	40
1644	Small molecule inhibitors of bromodomain-acetyl-lysine interactions. 2015 , 10, 22-39	135
1643	Chromatin signatures of cancer. 2015 , 29, 238-49	128
1642	Crowdsourcing in pharma: a strategic framework. 2015 , 20, 874-83	24
1641	Unexpected off-targets and paradoxical pathway activation by kinase inhibitors. 2015 , 10, 234-45	27
1640	Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization. 2015 , 58, 1281-97	41
1639	Protein lysine acetylation by p300/CBP. 2015 , 115, 2419-52	251
1638	Germinal centres and B cell lymphomagenesis. 2015 , 15, 172-84	272
1637	Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. 2015 , 194, 3180-90	48
1636	Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation. 2015 , 290, 2744-58	43
1635	Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2. 2015 , 466, 337-46	27

1634	Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. 2015 , 150, 265-78	29
1633	The BET family member BRD4 interacts with OCT4 and regulates pluripotency gene expression. 2015 , 4, 390-403	54
1632	Multifaceted Roles of Crystallography in Modern Drug Discovery. 2015 ,	1
1631	Going for broke: targeting the human cancer pseudokinome. 2015 , 465, 195-211	24
1630	Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation. 2015 , 11, 1295-304	15
1629	Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains. 2015 , 6, 1381-1386	52
1628	Targeting GLI factors to inhibit the Hedgehog pathway. 2015 , 36, 547-58	76
1627	Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. 2015 , 22, 689-703	103
1626	Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells. 2015 , 112, E4448-57	34
1625	Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension. 2015 , 117, 525-35	106
1624	Small molecules targeting microRNA for cancer therapy: Promises and obstacles. 2015 , 219, 237-247	66
1623	An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. 2015 , 6, 5400-5408	110
1622	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. 2015 , 271, 241-50	19
1621	Prise en charge des cancers ORL rares : synthèse des recommandations du réseau d'expertise français REFCOR. 2015 , 17, 256-258	3
1620	Histone profiles in cancer. 2015 , 154, 87-109	5
1619	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. 2015 , 58, 6151-78	65
1618	The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. 2015 , 29, 1507-23	116
1617	Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. 2015 , 6, 128-41	116

1616	Writers, Readers, and Erasers of Epigenetic Marks. 2015 , 31-66	7
1615	Emerging Epigenetic Therapies Bromodomain Ligands. 2015 , 495-524	1
1614	Personalized Therapy Epigenetic Profiling as Predictors of Prognosis and Response. 2015 , 677-698	1
1613	Targeting BET bromodomains for cancer treatment. 2015 , 7, 487-501	109
1612	Beating the odds: BETs in disease. 2015 , 40, 468-79	111
1611	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. 2015 , 58, 5649-73	60
1610	Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?. 2015 , 121, 179-87	11
1609	Non-canonical Bromodomain within DNA-PKcs Promotes DNA Damage Response and Radioresistance through Recognizing an IR-Induced Acetyl-Lysine on H2AX. 2015 , 22, 849-61	12
1608	CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. 2015 , 308, L962-72	41
1607	MYC Is a Major Determinant of Mitotic Cell Fate. 2015 , 28, 129-40	85
1606	Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. 2015 , 99, 248-57	67
1605	Probing the epigenome. 2015 , 11, 542-5	29
1604	Fragments in bromodomain drug discovery. 2015 , 6, 1587-1604	15
1603	Characterization of CpG sites that escape methylation on the inactive human X-chromosome. 2015 , 10, 810-8	8
1602	BET bromodomain inhibitors in leukemia. 2015 , 43, 718-31	27
1601	Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules. 2015 , 10, 2246-56	59
1600	Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia. 2015 , 29, 2317-27	17
1599	NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. 2015 , 10, 1797-804	242

1598	Epigenetic Therapy of Cancer. 2015 , 325-358	2
1597	Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. 2015 , 1856, 62-72	39
1596	Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. 2015 , 22, 755-63	591
1595	Structure-Based Design of β -Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. 2015 , 58, 4927-39	66
1594	The Bromodomain as the Acetyl-Lysine Binding Domain in Gene Transcription. 2015 , 1-26	0
1593	The role of BPTF in melanoma progression and in response to BRAF-targeted therapy. 2015 , 107,	55
1592	Selectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuations. 2015 , 11, e1004081	17
1591	Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. 2015 , 24, 3982-93	41
1590	Novel therapeutic strategies for multiple myeloma. 2015 , 43, 732-41	79
1589	BRD4 inhibitor inhibits colorectal cancer growth and metastasis. 2015 , 16, 1928-48	58
1588	Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. 2015 , 12, 317-28	37
1587	Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. 2015 , 16, 580-8	15
1586	BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. 2015 , 125, 2724-8	30
1585	RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells. 2015 , 12, 36	32
1584	Polycomb-mediated silencing in neuroendocrine prostate cancer. 2015 , 7, 40	70
1583	Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. 2015 , 4, 2	40
1582	NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. 2015 , 211, 404-8	28
1581	Direct photocapture of bromodomains using tropolone chemical probes. 2015 , 6, 1018-1023	8

1580	BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. 2015 , 58, 1028-39	214
1579	Direct and indirect targeting of MYC to treat acute myeloid leukemia. 2015 , 76, 35-46	27
1578	Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. 2015 , 127, 191-226	10
1577	9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. 2015 , 58, 2718-36	50
1576	Cancer therapy and replication stress: forks on the road to perdition. 2015 , 69, 91-138	20
1575	Exploiting replicative stress to treat cancer. 2015 , 14, 405-23	188
1574	Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. 2015 , 10, 460-6	46
1573	One-pot synthesis of 3,4,5-trisubstituted 1,2,4-triazoles via the addition of hydrazides to activated secondary amides. 2015 , 17, 1184-7	55
1572	NUT midline carcinoma presenting with bilateral ovarian metastases: a case report. 2015 , 34, 136-42	2
1571	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. 2015 , 10, S1-63	102
1570	Epigenetics in rheumatoid arthritis. 2015 , 27, 76-82	89
1569	The role of the synovial fibroblast in rheumatoid arthritis pathogenesis. 2015 , 27, 175-82	78
1568	Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. 2015 , 29, 658-71	100
1567	Molecular Mechanisms of AID Function. 2015 , 305-344	1
1566	Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. 2015 , 27, 57-63	16
1565	Perturbation of the c-Myc-Max protein-protein interaction via synthetic β -helix mimetics. 2015 , 58, 3002-24	63
1564	How many molecules does it take to tell a story? Case studies, language, and an epistemic view of medicinal chemistry. 2015 , 10, 949-56	12
1563	Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. 2015 , 58, 2553-9	74

1562	Development of methyl isoxazoleazepines as inhibitors of BET. 2015 , 25, 1842-8	21
1561	The Epigenetic Reader BRD2 as a Specific Modulator of PAI-1 Expression in Lipopolysaccharide-Stimulated Mouse Primary Astrocytes. 2015 , 40, 2211-9	11
1560	Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice. 2015 , 212, 1771-81	40
1559	Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression. 2015 , 12, 1986-96	68
1558	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. 2015 , 21, 1163-71	275
1557	Epigenetic-based therapy: From single- to multi-target approaches. 2015 , 69, 121-31	32
1556	Discovery of Chemical Inhibitors of Human Bromodomains. 2015 , 115, 11625-68	82
1555	Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma. 2015 , 31, 720-731	3
1554	Targeting cancer epigenetics: Linking basic biology to clinical medicine. 2015 , 95, 56-64	31
1553	JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. 2015 , 29, 2123-39	54
1552	Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. 2015 , 8, 37	25
1551	Targeting epigenetic regulations in cancer. 2016 , 48, 97-109	41
1550	Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression. 2015 , 14, 2167-74	52
1549	CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. 2015 , 112, 10768-73	150
1548	Binding Kinetics versus Affinities in BRD4 Inhibition. 2015 , 55, 1926-35	19
1547	Targeting Transcription Factors in Cancer. 2015 , 1, 53-65	149
1546	An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. 2015 , 28, 472-485	55
1545	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. 2015 , 60, 307-18	127

1544	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. 2015 , 43, 5880-97	121
1543	21(st) Century Cures Act: An Act of Cure or Diagnosis?. 2015 , 18, 295-8	5
1542	NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. 2015 , 14, 2382-2389	28
1541	BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice. 2015 , 18, 1464-73	149
1540	Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?. 2015 , 50, 1393-404	8
1539	Acute TNF-induced repression of cell identity genes is mediated by NFB-directed redistribution of cofactors from super-enhancers. 2015 , 25, 1281-94	49
1538	BET bromodomains regulate transforming growth factor- β -induced proliferation and cytokine release in asthmatic airway smooth muscle. 2015 , 290, 9111-21	44
1537	A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs). 2015 , 20, 748-59	22
1536	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. 2015 , 12, 1300-13	32
1535	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015 , 525, 538-42	50.4 345
1534	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. <i>Nature</i> , 2015 , 525, 543-547	50.4 327
1533	The potential of DNA modifications as biomarkers and therapeutic targets in oncology. 2015 , 15, 1325-37	19
1532	Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. 2015 , 43, 7790-804	26
1531	Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. 2015 , 14, 693-720	141
1530	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). 2015 , 4, 261-84	34
1529	Epigenetic drugs for cancer therapy. 2015 , 397-423	0
1528	Emerging Target Families: Intractable Targets. 2016 , 232, 43-58	8
1527	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. 2015 , 75, 5106-5119	155

1526	Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity. 2015 , 35, 15062-72	47
1525	NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. 2015 , 60, 847-59	98
1524	Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. 2015 , 60, 561-70	41
1523	Nuclear protein in testis midline carcinoma with unusual elevation of β -tubulin and synaptophysin positivity: a case report and review of the literature. 2015 , 15, 1199-213	9
1522	Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies. 2015 , 23, 1-14	10
1521	The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications. 2015 , 169, 14-31	22
1520	Targeting BRG1 chromatin remodeler via its bromodomain for enhanced tumor cell radiosensitivity in vitro and in vivo. 2015 , 14, 597-607	20
1519	Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?. 2015 , 263, 279-301	40
1518	B cells in chronic graft-versus-host disease. 2015 , 21, 16-23	63
1517	Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. 2015 , 36, 192-201	52
1516	Epigenetic targets for novel therapies of lung diseases. 2015 , 147, 91-110	60
1515	Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. 2015 , 24, 879-91	40
1514	A universal homogeneous assay for high-throughput determination of binding kinetics. 2015 , 468, 42-9	40
1513	Epigenetic pathways and glioblastoma treatment: insights from signaling cascades. 2015 , 116, 351-63	16
1512	Small-molecule inhibitors of the Myc oncoprotein. 2015 , 1849, 525-43	102
1511	Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells. 2015 , 165, 126-42	30
1510	SWI/SNF chromatin remodeling and human malignancies. 2015 , 10, 145-71	186
1509	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. 2015 , 56, 1742-9	9

1508	Bromodomain inhibition in diffuse large B-cell lymphoma--giving MYC a brake. 2015 , 21, 4-6	14
1507	Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. 2015 , 21, 113-22	101
1506	Targeting the histone orthography of cancer: drugs for writers, erasers and readers. 2015 , 172, 2716-32	66
1505	Epigenetics and Cancer. 2015 , 67-78.e3	
1504	Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. 2016 , 7, 135-48	19
1503	Predicting and Monitoring Responses to Epigenetic Drugs. 2016 , 373-406	1
1502	Structure-Based Ligand Design II: With Structure of Protein/Lead Compound Complex Unavailable. 2016 , 61-108	
1501	Epigenetic Alterations in Endocrine-Dependent Cancers: Implications of Endocrine Dysfunctions. 2016 , 351-374	
1500	Prospective Advances in Medical Epigenetics. 2016 , 891-910	
1499	Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Flt1. 2016 , 7, 24125-40	35
1498	BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. 2016 , 7, 43504-43517	24
1497	HEDD: the human epigenetic drug database. 2016 , 2016,	29
1496	Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7. 2016 , 17,	8
1495	The Bromodomain as an Acetyl-Lysine Reader Domain. 2016 , 97-111	1
1494	BET inhibition as a new strategy for the treatment of gastric cancer. 2016 , 7, 43997-44012	35
1493	Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia. 2016 , 7, 25208-23	15
1492	Epigenetic Readers Interpreting the Lysine Methylome Biological Roles and Drug Discovery. 2016 , 273-304	
1491	Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. 2016 , 8, e620	46

1490	Accelerating target discovery using pre-competitive open science-patients need faster innovation more than anyone else. 2016 , 10, ed57	7
1489	DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. 2016 , 2016, 6072357	19
1488	Altered Chromatin Signaling in Cancer. 2016 , 329-346	
1487	Networks and Consortia for Epigenetic Drug Discovery. 2016 , 143-166	1
1486	BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. 2016 , 9, 5943-5953	36
1485	BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. 2016 , 6, 219-30	63
1484	Toxicology and Epigenetics. 2016 , 555-583	
1483	The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. 2016 , 17,	147
1482	Process of Fragment-Based Lead Discovery-A Perspective from NMR. 2016 , 21,	20
1481	Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb. 2016 , 44, 7527-39	66
1480	Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation. 2016 , 11, e0163392	16
1479	Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A. 2016 , 11, e0154607	14
1478	Frapid: achieving full automation of FRAP for chemical probe validation. 2016 , 7, 422-41	
1477	Drug Discovery Methods. 2016 , 63-95	4
1476	Bromodomains as Anticancer Targets. 2016 , 239-271	
1475	Advances in understanding the pathogenesis of graft-versus-host disease. 2016 , 173, 190-205	54
1474	Epigenetic regulation of epithelial-mesenchymal transition. 2016 , 73, 4493-4515	73
1473	Discovery and Development of Small Molecules Targeting Epigenetic Enzymes with Computational Methods. 2016 , 75-112	2

1472	Progress in the Development of non-BET Bromodomain Chemical Probes. 2016 , 11, 477-87	35
1471	Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. 2016 , 12, 672-9	102
1470	Cytological features of NUT midline carcinoma arising in sino-nasal tract and parotid gland: Report of two new cases and review of the literature. 2016 , 44, 753-6	16
1469	Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology. 2016 , 8, 1655-80	41
1468	Overexpression of bromodomain factor 3 in <i>Trypanosoma cruzi</i> (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors. 2016 , 283, 2051-66	18
1467	Epigenetic Pharmacology. 2016 , 1-25	
1466	Epigenetic polypharmacology: from combination therapy to multitargeted drugs. 2016 , 8, 105	96
1465	Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals. <i>Nature</i> , 2016 , 540, 428-432	50.4 79
1464	The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia. 2016 , 81, 61-66	14
1463	Multivalent Histone and DNA Engagement by a PHD/BRD/PWWP Triple Reader Cassette Recruits ZMYND8 to K14ac-Rich Chromatin. 2016 , 17, 2724-2737	54
1462	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. 2016 , 9, 134	53
1461	Exploring the role of water in molecular recognition: predicting protein ligandability using a combinatorial search of surface hydration sites. 2016 , 28, 344007	20
1460	The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis. 2016 , 7, 10869	17
1459	BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS. 2016 , 6, 23770	36
1458	BET Bromodomain Proteins as Cancer Therapeutic Targets. 2016 , 81, 123-129	44
1457	In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. 2016 , 6, 39032	19
1456	Drugging the undruggables: exploring the ubiquitin system for drug development. 2016 , 26, 484-98	279
1455	Histone Modifications and Cancer. 2016 , 8, a019521	328

1454	RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. 2016 , 247, 48-57	74
1453	GENE EXPRESSION. Unwinding inducible gene expression. 2016 , 352, 1058-9	2
1452	NUT Midline Carcinoma Masquerading As a Thymic Carcinoma. 2016 , 34, e126-9	6
1451	Inhibition of BET bromodomains alleviates inflammation in human RPE cells. 2016 , 110-111, 71-9	17
1450	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. 2016 , 22, 4259-70	28
1449	Epigenetic Determinants of Cancer. 2016 , 8,	501
1448	RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription. 2016 , 165, 357-71	142
1447	BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer. 2016 , 15, 1029-42	71
1446	Epigenetic regulators and their impact on therapy in acute myeloid leukemia. 2016 , 101, 269-78	35
1445	Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. 2016 , 29, 464-476	99
1444	BET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation. 2016 , 196, 4132-42	34
1443	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. 2016 , 15, 533-50	555
1442	Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. 2016 , 12, 504-10	32
1441	BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. 2016 , 23, 540-8	170
1440	An Advanced Tool To Interrogate BRD9. 2016 , 59, 4459-61	12
1439	Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. 2016 , 352, aad7993	99
1438	BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. 2016 , 6, 612-29	179
1437	Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases. 2016 , 41, 295-311	58

1436	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors. 2016 , 26, 2931-2935	39
1435	Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice. 2016 , 300, 47-54	24
1434	The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. 2016 , 101, 1010-7	40
1433	Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. 2016 , 30, 459-473	83
1432	Phospho-BRD4: transcription plasticity and drug targeting. 2016 , 19, 17-22	28
1431	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. 2016 , 59, 8787-8803	32
1430	Genetically Encoded Voltage Indicators. 2016 , 252-269	2
1429	Computational Chemical Biology of Methyllysine Histone Effectors. 2016 , 273-296	
1428	BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. 2016 , 17, 212-221	32
1427	Chromatin Landscape of the IRF Genes and Role of the Epigenetic Reader BRD4. 2016 , 36, 470-5	14
1426	Chemical genetics approaches for selective intervention in epigenetics. 2016 , 33, 186-94	20
1425	Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. 2016 , 7, e2365	24
1424	Small-Molecule Targeting of BET Proteins in Cancer. 2016 , 131, 21-58	49
1423	BRD4 Phosphorylation Regulates HPV E2-Mediated Viral Transcription, Origin Replication, and Cellular MMP-9 Expression. 2016 , 16, 1733-1748	44
1422	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. 2016 , 16, 2003-16	48
1421	Structural features and inhibitors of bromodomains. 2016 , 19, 3-15	14
1420	Epigenomic Consequences of Coding and Noncoding Driver Mutations. 2016 , 2, 585-605	7
1419	Preparation, Biochemical Analysis, and Structure Determination of the Bromodomain, an Acetyl-Lysine Binding Domain. 2016 , 573, 321-43	7

1418	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. 2016 , 16, 644-56	48
1417	Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE mice. 2016 , 223, 428-432	11
1416	Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. 2016 , 59, 8889-8912	43
1415	Epigenetics, Energy Balance, and Cancer. 2016 ,	2
1414	Epigenetics, Enhancers, and Cancer. 2016 , 29-53	1
1413	ERK5 kinase activity is dispensable for cellular immune response and proliferation. 2016 , 113, 11865-11870	49
1412	Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. 2016 , 16, 1366-1378	47
1411	BET bromodomain is a novel regulator of TAZ and its activity. 2016 , 1859, 1527-1537	12
1410	BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells. 2016 , 79, 66-76	24
1409	Epigenetics of hematopoiesis and hematological malignancies. 2016 , 30, 2021-2041	79
1408	Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening. 2016 , 7, 1213-1218	14
1407	BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling. 2016 , 76, 6555-6567	82
1406	JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms. 2016 , 35, 1186-94	14
1405	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. 2016 , 291, 23756-23768	37
1404	Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF- β -dependent mechanisms. 2016 , 113, E4558-66	35
1403	Role of BET proteins in castration-resistant prostate cancer. 2016 , 19, 29-38	12
1402	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. 2016 , 15, 2553-2562	38
1401	Mechanisms of Nucleosome Dynamics In Vivo. 2016 , 6,	19

1400	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. 2016 , 122, 3632-3640	98
1399	BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. 2016 , 5, 1183-93	38
1398	Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. 2016 , 122, 20-33	121
1397	Epigenetics and Fragment-Based Drug Discovery. 2016 , 355-370	
1396	Late Stage C ₂ H Activation of a Privileged Scaffold; Synthesis of a Library of Benzodiazepines. 2016 , 358, 98-109	14
1395	Understanding Protein-Protein Interactions: Essential Players in (Patho)physiology (Part 1). 2016 , 17, 644-5	0
1394	AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. 2016 , 15, 2563-2574	94
1393	Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors. 2016 , 68, 236-44	16
1392	Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. 2016 , 59, 9305-9320	39
1391	Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153). 2016 , 59, 7801-17	46
1390	Epigenetic Mechanisms as Key Regulators in Disease. 2016 , 37-66	
1389	Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF- α Production. 2016 , 64, 1378-83	6
1388	The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. 2016 , 6, 24100	41
1387	BRD4 mediates NF- κ B-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation. 2016 , 311, L1183-L1201	62
1386	BET Bromodomain as a Target of Epigenetic Therapy. 2016 , 64, 540-7	44
1385	Epigenetics in Cardiac Disease. 2016 ,	2
1384	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. 2016 , 16, 2829-2837	226
1383	Targeting the cancer epigenome for therapy. 2016 , 17, 630-41	649

1382	Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes. 2016 , 7,	48
1381	Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to H CPMG Ligand-Observed NMR. 2016 , 11, 3154-3164	34
1380	Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1. 2016 , 117, 35-45	18
1379	JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma. 2016 , 36, 1989-96	28
1378	Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains. 2016 , 16, 3138-3145	19
1377	Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. 2016 , 64, 163-175	32
1376	Suppression of T17-mediated pathology through BET bromodomain inhibition. 2016 , 19, 39-44	2
1375	Chemical probes and inhibitors of bromodomains outside the BET family. 2016 , 7, 2246-2264	39
1374	Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. 2016 , 127, 42-52	171
1373	Efficacy of Combined Epigenetic Therapies. 2016 , 347-371	
1372	Next-generation phenotypic screening. 2016 , 8, 1331-47	34
1371	The solvation structure of alprazolam. 2016 , 18, 22416-25	6
1370	Clinical trials for BET inhibitors run ahead of the science. 2016 , 19, 45-50	165
1369	The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. 2016 , 213, 1459-77	73
1368	BRD4 regulates fructose-inducible lipid accumulation-related genes in the mouse liver. 2016 , 65, 1478-88	12
1367	Concepts to Target MYC in Pancreatic Cancer. 2016 , 15, 1792-8	54
1366	Rewiring the solid tumor epigenome for cancer therapy. 2016 , 16, 977-87	6
1365	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. 2016 , 15, 2030-41	39

1364	OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. 2016 , 139, 2047-55	84
1363	2-Aryl-5-carboxytetrazole as a New Photoaffinity Label for Drug Target Identification. 2016 , 138, 14609-14615	70
1362	The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors. 2016 , 19, 51-56	4
1361	Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. 2016 , 6, 30846	23
1360	Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET. 2016 , 11, 2575-2581	16
1359	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. 2016 , 30, 764-778	84
1358	Drug discovery: Doubling down on BET inhibition. 2016 , 12, 991-992	1
1357	Enhancers and their dynamics during hematopoietic differentiation and emerging strategies for therapeutic action. 2016 , 590, 4084-4104	6
1356	STAT Proteins in Cancer. 2016 , 33-47	0
1355	Relative Binding Free Energy Calculations Applied to Protein Homology Models. 2016 , 56, 2388-2400	40
1354	The control of male fertility by spermatid-specific factors: searching for contraceptive targets from spermatozoon's head to tail. 2016 , 7, e2472	29
1353	Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth. 2016 , 291, 26647-26657	15
1352	Design and characterization of bivalent BET inhibitors. 2016 , 12, 1089-1096	88
1351	Potent and selective bivalent inhibitors of BET bromodomains. 2016 , 12, 1097-1104	82
1350	Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. 2016 , 6, 1215-1229	41
1349	Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. 2016 , 2, e1600760	64
1348	Epigenetic drug discovery: breaking through the immune barrier. 2016 , 15, 835-853	102
1347	MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. 2016 , 2, 16008	24

1346	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. 2016 , 76, 6320-6330	85
1345	Biomarkers for Drug Discovery and Development. 2016 , 64, 55-59	
1344	Clinical and molecular insights into adenoid cystic carcinoma: Neural crest-like stemness as a target. 2016 , 1, 60-77	8
1343	Connecting HIV-1 integration and transcription: a step toward new treatments. 2016 , 590, 1927-39	10
1342	STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy. 2016 , 11, 795-801	28
1341	Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen. 2016 , 128, 2002-2010	32
1340	NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains. 2016 , 17, 1456-63	15
1339	Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue. 2016 , 22, 2605-10	29
1338	Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening. 2016 , 38, 39-44	9
1337	MYC Is a Crucial Mediator of TGF β -Induced Invasion in Basal Breast Cancer. 2016 , 76, 3520-30	12
1336	The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model. 2016 , 8, 42	10
1335	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. 2016 , 76, 4470-80	38
1334	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors. 2016 , 121, 294-299	12
1333	Prediction of (19)F NMR Chemical Shifts in Labeled Proteins: Computational Protocol and Case Study. 2016 , 13, 2376-86	18
1332	PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. 2016 , 113, 7124-9	427
1331	The molecular hallmarks of epigenetic control. 2016 , 17, 487-500	1256
1330	Senescence Can Be BETter without the SASP?. 2016 , 6, 576-8	2
1329	GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. 2016 , 7, 552-7	38

1328	NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds. 2016 , 37, 984-93	15
1327	Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. 2016 , 62, 681-94	94
1326	In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. 2016 , 15, 1823-33	20
1325	Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes. 2016 , 15, 310-22	28
1324	BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. 2016 , 15, 519-530	95
1323	BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. 2016 , 7, 22	37
1322	Chemical probes: A shared toolbox. <i>Nature</i> , 2016 , 533, S60-1	50.4 6
1321	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. 2016 , 6, 1006-21	71
1320	Clinical progress and pharmacology of small molecule bromodomain inhibitors. 2016 , 33, 58-66	60
1319	Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer. 2016 , 17, 10	31
1318	Epigenetic dysregulation of interleukin 8 (CXCL8) hypersecretion in cystic fibrosis airway epithelial cells. 2016 , 476, 431-437	13
1317	RVX-297- a novel BD2 selective inhibitor of BET bromodomains. 2016 , 477, 62-67	39
1316	First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. 2016 , 12, 1297-302	23
1315	Can histone proteins promote the growth of melanoma?. 2016 , 3, 1-4	2
1314	The Generation of a Library of Bromodomain-Containing Protein Modulators Expedited by Continuous Flow Synthesis. 2016 , 2016, 2000-2012	9
1313	Chemical probes for methyl lysine reader domains. 2016 , 33, 135-41	17
1312	The role of enhancers in cancer. 2016 , 16, 483-93	201
1311	Small-Molecule PROTACS: New Approaches to Protein Degradation. 2016 , 55, 1966-73	338

1310	Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. 2016 , 59, 1642-7	68
1309	The Intersection of Structural and Chemical Biology - An Essential Synergy. 2016 , 23, 173-182	14
1308	Epigenomic regulation of oncogenesis by chromatin remodeling. 2016 , 35, 4423-36	64
1307	Readers of poly(ADP-ribose): designed to be fit for purpose. 2016 , 44, 993-1006	141
1306	NUT Carcinoma of the Sublingual Gland. 2016 , 10, 362-6	20
1305	Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. 2016 , 59, 1330-9	126
1304	Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature. 2016 , 55, 140-6	17
1303	Applying α -Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. 2016 , 13, 683-8	11
1302	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. 2016 , 164, 293-309	259
1301	Targeting transcription factors by small compounds--Current strategies and future implications. 2016 , 107, 1-13	48
1300	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. 2016 , 14, 324-31	120
1299	Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration. 2016 , 64, 316-325	26
1298	Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells. 2016 , 24, 592-606	80
1297	Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. 2016 , 76, 1313-9	23
1296	Novel therapeutic targets in advanced urothelial carcinoma. 2016 , 98, 106-15	33
1295	Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb Family. 2016 , 7, 139-44	42
1294	The Bromodomain: A New Target in Emerging Epigenetic Medicine. 2016 , 11, 598-608	77
1293	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. 2016 , 30, 1531-41	22

1292	Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform. 2016 , 44, e88	43
1291	Which therapeutic strategy will achieve a cure for HIV-1?. 2016 , 18, 14-9	42
1290	Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. 2016 , 15, 1217-26	62
1289	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. 2016 , 70, 106-119	803
1288	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. 2016 , 6, 492-500	245
1287	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. 2016 , 3, e186-95	276
1286	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. 2016 , 3, e196-204	270
1285	Epigenetic Regulation of Monocyte and Macrophage Function. 2016 , 25, 758-774	64
1284	The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC. 2016 , 22, 615-625	10
1283	Epigenetic regulation of cardiac fibrosis. 2016 , 92, 206-13	35
1282	Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties. 2016 , 10, 3723-37	108
1281	Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. 2016 , 469, 679-85	41
1280	Accurate calculation of the absolute free energy of binding for drug molecules. 2016 , 7, 207-218	169
1279	A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor. 2016 , 26, 1365-70	7
1278	7SK-BAF axis controls pervasive transcription at enhancers. 2016 , 23, 231-8	60
1277	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. 2016 , 16, 541-51	3
1276	Bromodomain and hedgehog pathway targets in small cell lung cancer. 2016 , 371, 225-39	30
1275	Targeting protein-protein interactions, a wide open field for drug design. 2016 , 19, 19-27	69

1274	Structure of the Brd4 ET domain bound to a C-terminal motif from Retroviral integrases reveals a conserved mechanism of interaction. 2016 , 113, 2086-91	43
1273	Citrullination-acetylation interplay guides E2F-1 activity during the inflammatory response. 2016 , 2, e1501257	46
1272	Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. 2016 , 1859, 564-71	28
1271	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. 2016 , 76, 1538-48	59
1270	Epigenetische Strategien in der Krebstherapie. 2016 , 22, 19-29	
1269	Probing Chromatin-modifying Enzymes with Chemical Tools. 2016 , 11, 689-705	12
1268	KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases. 2016 , 59, 1249-70	50
1267	Therapeutics Targeting Protein Acetylation Perturb Latency of Human Viruses. 2016 , 11, 669-80	6
1266	Epigenetics. 2016 , 203-221	
1265	A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. 2016 , 12, 180-7	100
1264	An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. 2016 , 48, 265-72	152
1263	C/EBP β creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4. 2016 , 18, 371-81	64
1262	MCM5 as a target of BET inhibitors in thyroid cancer cells. 2016 , 23, 335-47	36
1261	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. 2016 , 15, 1018-28	55
1260	A pot-economical and diastereoselective synthesis involving catalyst-free click reaction for fused-triazolobenzodiazepines. 2016 , 18, 2642-2646	43
1259	BET inhibitors in cancer therapeutics: a patent review. 2016 , 26, 505-22	28
1258	High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility. 2016 , 113, 3018-23	16
1257	High-Throughput Fragment Docking into the BAZ2B Bromodomain: Efficient in Silico Screening for X-Ray Crystallography. 2016 , 11, 800-7	26

1256	Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. 2016 , 76, 2376-83	11
1255	Open Access Could Transform Drug Discovery: A Case Study of JQ1. 2016 , 11, 321-32	19
1254	Epigenetics: A primer for clinicians. 2016 , 30, 285-95	33
1253	MYC regulates the antitumor immune response through CD47 and PD-L1. 2016 , 352, 227-31	651
1252	The impact of next-generation sequencing on the DNA methylation-based translational cancer research. 2016 , 169, 1-18.e1	43
1251	A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain. 2016 , 7, 2322-2330	71
1250	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. 2016 , 22, 2470-81	112
1249	Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics. 2016 , 24, 707-18	92
1248	Hsp90 as a "Chaperone" of the Epigenome: Insights and Opportunities for Cancer Therapy. 2016 , 129, 107-40	19
1247	4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1). 2016 , 59, 1518-30	44
1246	Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. 2016 , 59, 1634-41	65
1245	The Gross Appearance of a NUT Midline Carcinoma. 2016 , 24, 85-8	6
1244	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016 , 529, 413-417	50.4 363
1243	Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform. 2016 , 21, 201-11	14
1242	Bromodomains: Structure, function and pharmacology of inhibition. 2016 , 106, 1-18	141
1241	An epigenetic gateway to brain tumor cell identity. 2016 , 19, 10-9	65
1240	Epigenome-based personalized medicine in human cancer. 2016 , 8, 119-33	57
1239	Reading between the Lines: "ADD"-ing Histone and DNA Methylation Marks toward a New Epigenetic "Sum". 2016 , 11, 554-63	17

1238	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. 2016 , 22, 2534-44	79
1237	Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. 2016 , 59, 1565-79	60
1236	Emerging Bladder Cancer Biomarkers and Targets of Therapy. 2016 , 43, 63-76	17
1235	The role of osteoclast differentiation and function in skeletal homeostasis. 2016 , 159, 1-8	89
1234	Protein-Observed Fluorine NMR: A Bioorthogonal Approach for Small Molecule Discovery. 2016 , 59, 5158-71	102
1233	Integrated genomic characterization of IDH1-mutant glioma malignant progression. 2016 , 48, 59-66	185
1232	Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. 2016 , 59, 1271-98	143
1231	Advances in discovering small molecules to probe protein function in a systems context. 2016 , 30, 28-36	11
1230	New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition. 2016 , 59, 1492-500	36
1229	Histone variant H2A.Z.2: A novel driver of melanoma progression. 2016 , 3, e1073417	15
1228	Current challenges and novel treatment strategies in double hit lymphomas. 2016 , 7, 52-64	19
1227	Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300. 2016 , 7, 151-5	46
1226	Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IB kinase-dependent NF- κ B activation in rheumatoid fibroblast-like synoviocytes. 2016 , 55, 173-84	58
1225	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. 2016 , 55, 397-405	61
1224	Microfluidic Mobility Shift Profiling of Lysine Acetyltransferases Enables Screening and Mechanistic Analysis of Cellular Acetylation Inhibitors. 2016 , 11, 734-41	13
1223	MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. 2016 , 35, 1609-18	80
1222	Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. 2016 , 35, 1797-810	77
1221	Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. 2016 , 59, 1440-54	95

1220	A Genetically Encoded FRET Probe to Detect Intranucleosomal Histone H3K9 or H3K14 Acetylation Using BRD4, a BET Family Member. 2016 , 11, 729-33	22
1219	Chromatin deregulation in disease. 2016 , 125, 75-93	68
1218	Elucidating the mechanisms of transcription regulation during heart development by next-generation sequencing. 2016 , 61, 5-12	2
1217	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. 2016 , 59, 1410-24	108
1216	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. 2016 , 35, 833-45	100
1215	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. 2016 , 59, 1425-39	135
1214	Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains. 2016 , 7, 145-50	23
1213	The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. 2017 , 36, 122-132	93
1212	Epigenetic regulation of bone cells. 2017 , 58, 76-89	16
1211	Pharmacological Inhibition of Bromodomain Proteins Suppresses Retinal Inflammatory Disease and Downregulates Retinal Th17 Cells. 2017 , 198, 1093-1103	17
1210	CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. 2017 , 484, 262-268	14
1209	MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. 2017 , 36, 3346-3356	53
1208	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. 2017 , 12, 353-369	27
1207	Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. 2017 , 60, 668-680	28
1206	Genomic targeting of epigenetic probes using a chemically tailored Cas9 system. 2017 , 114, 681-686	45
1205	The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. 2017 , 13, 389-395	139
1204	Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. 2017 , 114, E1072-E1080	75
1203	Structural basis for ELL2 and AFF4 activation of HIV-1 proviral transcription. 2017 , 8, 14076	22

1202	Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. 2017 , 15, 8	33
1201	The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21. 2017 , 391, 141-151	26
1200	Small-Molecule Inhibitors of the SOX18 Transcription Factor. 2017 , 24, 346-359	28
1199	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. 2017 , 7, 302-321	80
1198	Epigenetics in cancer stem cells. 2017 , 16, 29	195
1197	Cellular analysis of the action of epigenetic drugs and probes. 2017 , 12, 308-322	3
1196	Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. 2017 , 31, 2037-2047	42
1195	Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development. 2017 , 81,	36
1194	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. 2017 , 35, 335-341	45
1193	BRD4 Couples NF- κ B/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection. 2017 , 91,	52
1192	Post-translational selective intracellular silencing of acetylated proteins with de novo selected intrabodies. 2017 , 14, 279-282	10
1191	RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. 2017 , 31, 2219-2227	39
1190	A chemical probe toolbox for dissecting the cancer epigenome. 2017 , 17, 160-183	54
1189	MYC: Master Regulator of Immune Privilege. 2017 , 38, 298-305	49
1188	The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network. 2017 , 284, 1082-1095	14
1187	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. 2017 , 77, 2476-2487	115
1186	Targeting Cancer Cells with BET Bromodomain Inhibitors. 2017 , 7,	108
1185	An Atom-Economical Method To Prepare Enantiopure Benzodiazepines with N-Carboxyanhydrides. 2017 , 19, 1454-1457	16

1184	Archaeology: Digital maps illuminate ancient trade routes. <i>Nature</i> , 2017 , 543, 188-189	50.4	4
1183	BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. 2017 , 114, 2952-2957		65
1182	Marked for death: targeting epigenetic changes in cancer. 2017 , 16, 241-263		172
1181	Non-kinase targets of protein kinase inhibitors. 2017 , 16, 424-440		72
1180	BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. 2017 , 18, 229-236		7
1179	Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays. 2017 , 27, 2003-2009		7
1178	Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?. 2017 , 66, 168-179		80
1177	ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. <i>Nature</i> , 2017 , 543, 265-269	50.4	124
1176	Cancer epigenetics: Reading the future of leukaemia. <i>Nature</i> , 2017 , 543, 186-188	50.4	7
1175	DNA Hypomethylating Drugs in Cancer Therapy. 2017 , 7,		69
1174	Transcriptional Addiction in Cancer. 2017 , 168, 629-643		491
1173	Coordinate activities of BRD4 and CDK9 in the transcriptional elongation complex are required for TGFβ-induced Nox4 expression and myofibroblast transdifferentiation. 2017 , 8, e2606		27
1172	Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation. 2017 , 65, 1068-1080.e5		81
1171	Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140. 2017 , 2,		28
1170	Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. 2017 , 394, 76-87		73
1169	Selective targeting of epigenetic reader domains. 2017 , 12, 449-463		15
1168	BET Proteins: An Approach to Future Therapies in Transplantation. 2017 , 17, 2254-2262		13
1167	'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia. 2017 , 23, 264-281		3

1166	Drug Discovery Targeting Bromodomain-Containing Protein 4. 2017 , 60, 4533-4558	171
1165	Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma. 2017 , 41, 1947-1956	43
1164	Lymphoma classification update: B-cell non-Hodgkin lymphomas. 2017 , 10, 405-415	32
1163	Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation from Latency. 2017 , 21, 507-517.e5	19
1162	Super-Enhancer-Driven Transcriptional Dependencies in Cancer. 2017 , 3, 269-281	124
1161	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. 2017 , 471, 271-280	13
1160	Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. 2017 , 108, 563-569	161
1159	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. 2017 , 56, 5738-5743	146
1158	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. 2017 , 129, 5832-5837	13
1157	Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. 2017 , 77, 2976-2989	73
1156	Mediastinal Lesions. 2017 ,	
1155	Developing Spindlin1 small-molecule inhibitors by using protein microarrays. 2017 , 13, 750-756	35
1154	Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors. 2017 , 6, e332	27
1153	Bioprobes. 2017 ,	4
1152	ETS-targeted therapy: can it substitute for MEK inhibitors?. 2017 , 6, 16	17
1151	Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. 2017 , 114, E4184-E4192	64
1150	SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. 2017 , 21, 569-579.e6	54
1149	Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4. 2017 , 36, 5177-5188	25

1148	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. 2017 , 60, 3887-3901	23
1147	Quantifying Protein Concentrations Using Smartphone Colorimetry: A New Method for an Established Test. 2017 , 94, 941-945	27
1146	Regulation of the human papillomavirus type 16 late promoter by transcriptional elongation. 2017 , 507, 179-191	11
1145	PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. 2017 , 7, 884-899	127
1144	HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues. 2017 , 16, 388-396	35
1143	Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature. 2017 , 64, e26334	5
1142	Bromodomain inhibitors and cancer therapy: From structures to applications. 2017 , 12, 323-339	171
1141	Bromodomain Histone Readers and Cancer. 2017 , 429, 2003-2010	60
1140	Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. 2017 , 32, 27-41.e4	96
1139	BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. 2017 , 9,	135
1138	Selective BET bromodomain inhibition as an antifungal therapeutic strategy. 2017 , 8, 15482	25
1137	Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function. 2017 , 66, 517-532.e9	123
1136	Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1. 2017 , 7, 1684	13
1135	Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4. 2017 , 57, 1677-1690	27
1134	Tumor Microenvironment-Responsive Multistaged NanoplatforM for Systemic RNAi and Cancer Therapy. 2017 , 17, 4427-4435	104
1133	Drugging the 'undruggable' cancer targets. 2017 , 17, 502-508	381
1132	Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps. 2017 , 292, 13284-13295	19
1131	BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. 2017 , 309, 491-497	6

1130	Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification. 2017 , 18, 1108-1122	19
1129	Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy. 2017 , 139, 137-147	13
1128	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. 2017 , 60, 4805-4817	31
1127	Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). 2017 , 26, 803-811	26
1126	Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. 2017 , 137, 176-195	22
1125	Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer. 2017 , 16, 1739-1750	38
1124	Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. 2017 , 27, 3534-3541	22
1123	Molecular structures guide the engineering of chromatin. 2017 , 45, 7555-7570	14
1122	NUT Midline Carcinoma of the Sublingual Gland: Clinical Presentation and Review. 2017 , 11, 460-468	16
1121	Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. 2017 , 60, 3828-3850	42
1120	The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries. 2017 , 66, 102-116.e7	79
1119	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. 2017 , 16, 1054-1067	30
1118	BET proteins are a key component of immunoglobulin gene expression. 2017 , 9, 393-406	6
1117	Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. 2017 , 9, 482-497	50
1116	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. 2017 , 8, 14802	101
1115	Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. 2017 , 45, 6334-6349	55
1114	ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. 2017 , 31, 452-465	36
1113	Structural basis of PROTAC cooperative recognition for selective protein degradation. 2017 , 13, 514-521	460

1112	Dysregulation of BET proteins in levodopa-induced dyskinesia. 2017 , 102, 125-132	15
1111	Site-specific azide-acetyllysine photochemistry on epigenetic readers for interactome profiling. 2017 , 8, 4250-4256	20
1110	The cancer epigenome: Concepts, challenges, and therapeutic opportunities. 2017 , 355, 1147-1152	201
1109	Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay. 2017 , 8, 1322-1331	10
1108	N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment. 2017 , 7, 42108	11
1107	Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. 2017 , 16, 1041-1053	11
1106	Effect of small molecules on cell reprogramming. 2017 , 13, 277-313	11
1105	Targeting Chromatin Remodeling in Inflammation and Fibrosis. 2017 , 107, 1-36	20
1104	CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation. 2017 , 24, 9-23	27
1103	Link Between ER-Stress, PPAR-Alpha Activation, and BET Inhibition in Relation to Apolipoprotein A-I Transcription in HepG2 Cells. 2017 , 118, 2161-2167	8
1102	Discovery of a PCAF Bromodomain Chemical Probe. 2017 , 129, 845-849	9
1101	The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. 2017 , 21, 1300-1314	54
1100	In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity. 2017 , 90, 97-111	8
1099	Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF- β -mediated Nox4 expression. 2017 , 11, 390-402	64
1098	Cytopathologic and immunophenotypic changes in NUT midline carcinoma after targeted therapy. 2017 , 125, 70	1
1097	Silencing c-Myc translation as a therapeutic strategy through targeting PI3K and CK1 in hematological malignancies. 2017 , 129, 88-99	74
1096	Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. 2017 , 18, 246-262	280
1095	Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. 2017 , 60, 695-709	47

1094	Discovery of a PCAF Bromodomain Chemical Probe. 2017 , 56, 827-831	58
1093	Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. 2017 , 56, 15504-15505	22
1092	What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?. 2017 , 9, 839-842	
1091	Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. 2017 , 28, 3756-3772	11
1090	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. 2018 , 131, 95-107	26
1089	Spatially restricted loading of BRD2 at DNA double-strand breaks protects H4 acetylation domains and promotes DNA repair. 2017 , 7, 12921	19
1088	RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. 2017 , 92, 694-706	32
1087	DNA Methylation-Targeted Drugs. 2017 , 23, 270-276	15
1086	Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4. 2017 , 56, 5485-5495	13
1085	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. 2017 , 60, 8369-8384	
1084	Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. 2017 , 10,	54
1083	BRD4-NUT Fusion Oncoprotein and Its Significance in the Initiation and Progression of NUT Midline Carcinoma. 2017 , 129-135	
1082	Haploinsufficiency of the Chromatin Remodeler BPTF Causes Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and Dysmorphic Features. 2017 , 101, 503-515	37
1081	Drug Discovery and Chemical Biology of Cancer Epigenetics. 2017 , 24, 1120-1147	35
1080	The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression. 2017 , 95, 1574-1579	11
1079	Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from. 2017 , 474, 3817-3830	12
1078	WD40 repeat domain proteins: a novel target class?. 2017 , 16, 773-786	101
1077	Report and Application of a Tool Compound Data Set. 2017 , 57, 2699-2706	3

1076	CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of invasion. 2017 , 114, E9356-E9365	28
1075	Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues. 2017 , 15, 9352-9361	23
1074	In Situ Capture of Chromatin Interactions by Biotinylated dCas9. 2017 , 170, 1028-1043.e19	167
1073	The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. 2017 , 67, 1001-1012.e6	66
1072	Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations. 2017 , 2, 4760-4771	27
1071	Proteomics for Drug Discovery. 2017 ,	0
1070	Novel Drugs Targeting the Epigenome. 2017 , 3, 268-285	2
1069	Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family. 2017 , 19, 23934-23941	15
1068	BRD4 inhibitors block telomere elongation. 2017 , 45, 8403-8410	23
1067	Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation. 2017 , 12, 2619-2630	20
1066	The tale of a tail: histone H4 acetylation and the repair of DNA breaks. 2017 , 372,	48
1065	Bromodomain proteins: repairing DNA damage within chromatin. 2017 , 372,	25
1064	Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. 2017 , 16, 2627-2638	22
1063	Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment. 2017 , 27, 4606-4613	13
1062	Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer. 2017 , 23, 286-291	22
1061	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. 2017 , 20, 2833-2845	34
1060	A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors. 2017 , 7, 1436-1449	34
1059	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. 2017 , 8, 14400	63

1058	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs. 2017 , 69, 479-496	42
1057	BRD4 regulates adiponectin gene induction by recruiting the P-TEFb complex to the transcribed region of the gene. 2017 , 7, 11962	17
1056	Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking. 2017 , 57, 2584-2597	20
1055	Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations. 2017 , 7, 8857	21
1054	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. 2017 , 8, 16078	100
1053	Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma. 2017 , 12, 1031-1040	27
1052	Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains. 2017 , 8, 847-852	10
1051	Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma. 2017 , 9, 25887-25904	30
1050	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors. 2017 , 27, 4051-4055	31
1049	Family matters: How MYC family oncogenes impact small cell lung cancer. 2017 , 16, 1489-1498	47
1048	Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction. 2017 , 60, 6924-6941	24
1047	Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins. 2017 , 60, 6998-7011	20
1046	Bromodomain factors of BET family are new essential actors of pericentric heterochromatin transcriptional activation in response to heat shock. 2017 , 7, 5418	17
1045	Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family. 2017 , 350, 1700147	8
1044	Unveiling the folding mechanism of the Bromodomains. 2017 , 11, 99-104	0
1043	BET inhibitors: a novel epigenetic approach. 2017 , 23, 1776-1787	176
1042	Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. 2017 , 1, 1	63
1041	Integrin $\beta 4$ Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. 2017 , 7, 6174	6

1040	BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis. 2017 , 7, 6153	26
1039	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in and models of multiple myeloma by blockade of Ikaros and MYC signaling. 2017 , 102, 1776-1784	34
1038	Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. 2017 , 109,	60
1037	Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles. 2017 , 56, 12476-12480	21
1036	Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors. 2017 , 77, 5395-5408	16
1035	Bromodomain-containing Protein 4 Activates Voltage-gated Sodium Channel 1.7 Transcription in Dorsal Root Ganglia Neurons to Mediate Thermal Hyperalgesia in Rats. 2017 , 127, 862-877	12
1034	Exploring Protein-Protein Interactions as Drug Targets for Anti-cancer Therapy with In Silico Workflows. 2017 , 1647, 221-236	17
1033	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 2017 , 23, 1046-1054	102
1032	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 2017 , 23, 1063-1071	169
1031	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. 2017 , 23, 1055-1062	149
1030	Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles. 2017 , 129, 12650-12654	
1029	The Role of Bromodomain and Extraterminal Motif (BET) Proteins in Chromatin Structure. 2017 , 82, 37-43	24
1028	Ovarian cancer: how can resistance to chemotherapy be tackled?. 2017 , 13, 2737-2739	8
1027	Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers. 2017 , 179, 724-738	28
1026	Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer. 2017 , 60, 9990-10012	61
1025	miR-126-5p promotes retinal endothelial cell survival through SetD5 regulation in neurons. 2018 , 145,	24
1024	Synthetic transcription elongation factors license transcription across repressive chromatin. 2017 , 358, 1617-1622	68
1023	Neue Anwendungen der Klick-Chemie in Zellbiologie und Wirkstoffentwicklung. 2017 , 129, 15709-15711	7

1022	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. 2017 , 68, 731-744.e9	53
1021	Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells. 2017 , 8, 1467	55
1020	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. 2017 , 21, 1953-1967	89
1019	Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. 2017 , 8, 1298-1303	17
1018	Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. 2017 , 12, 510-512	22
1017	Epigenetics: Druggable targets for anti-cancer therapies. 2017 , 6, 79-86	1
1016	Epigenetic Modulators. 2017 , 227-227	2
1015	NUT carcinoma in children and adults: A multicenter retrospective study. 2017 , 64, e26693	49
1014	Cancer Genome Methylation: Biology, Biomarker and Therapeutic Opportunities. 2017 , 16-26	
1013	An Assay Based on SAMDI Mass Spectrometry for Profiling Protein Interaction Domains. 2017 , 139, 10320-10327	
1012	Discovery of a Covalent Kinase Inhibitor from a DNA-Encoded Small-Molecule Library [Protein Library Selection]. 2017 , 139, 10192-10195	48
1011	Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation. 2017 , 39, 116-125	27
1010	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. 2017 , 32, 9-25	110
1009	Role of epigenome in tumorigenesis and drug resistance. 2017 , 109, 663-668	14
1008	Epigenetische Strategien in der Krebstherapie. 2017 , 12, 18-28	
1007	Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. 2017 , 114, E5352-E5361	32
1006	Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration. 2017 , 14, 14	14
1005	A high-throughput colorimetric assay for detection of <i>Schistosoma mansoni</i> viability based on the tetrazolium salt XTT. 2017 , 10, 300	11

1004	BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma. 2017 , 50, 19	27
1003	Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. 2017 , 28, 254-269	46
1002	Development of New Positron Emission Tomography Radiotracer for BET Imaging. 2017 , 8, 17-21	10
1001	Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. 2017 , 105, 23-30	25
1000	Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities. 2017 , 21, 125-136	1
999	Lysine acetylation and cancer: A proteomics perspective. 2017 , 150, 297-309	91
998	The suppression of bromodomain and extra-terminal domain inhibits vascular inflammation by blocking NF- κ B and MAPK activation. 2017 , 174, 101-115	42
997	Genomic complexity of multiple myeloma and its clinical implications. 2017 , 14, 100-113	267
996	Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. 2017 , 28, 504-519	39
995	Exploiting receptor tyrosine kinase co-activation for cancer therapy. 2017 , 22, 72-84	21
994	Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors. 2017 , 35, 2351-2362	34
993	BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer. 2017 , 74, 231-243	19
992	Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. 2017 , 22, 157-164	33
991	Inhibition of BET bromodomain improves anemia in APC mice. 2017 , 58, 989-992	1
990	BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. 2017 , 45, 127-141	64
989	The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. 2017 , 23, 2027-2037	41
988	Global chemotherapy development for gastric cancer. 2017 , 20, 92-101	24
987	Synthetic Lethality in Cancer Therapeutics. 2017 , 1, 141-161	23

986	Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. 2017 , 94, 10-21	38
985	Targeted Protein Degradation by Small Molecules. 2017 , 57, 107-123	104
984	Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. 2017 , 23, 430-440	38
983	Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. 2017 , 31, 479-490	30
982	Bromodomain-containing protein 2 induces insulin resistance via the mTOR/Akt signaling pathway and an inflammatory response in adipose tissue. 2017 , 30, 92-103	9
981	BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells. 2018 , 39, 582-588	6
980	Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes. 2017 ,	5
979	BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. 2017 , 21, 3398-3405	91
978	Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis. 2017 , 8, 2217	98
977	Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4. 2017 , 7, 16272	20
976	A case of NUT (Nuclear Protein in Testis) Midline Carcinoma of the Ethmoid Sinuses. 2017 , 120, 1337-1342	1
975	Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. 2017 , 102, 2268-2280	29
974	Inhibitors of Epigenetic Regulation in Cancer. 2017 , 281-307	
973	Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents. 2017 , 2017, 460-469	5
972	The role of targeted therapy in the management of patients with AML. 2017 , 2017, 54-65	18
971	Fibroblasts and Fibroblast-like Synoviocytes. 2017 , 231-249.e4	3
970	Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. 2017 , 8, 495	36
969	Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer. 2017 , 32, 326-331	9

968	Association of high microvessel density and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. 2017 , 8, 52193-52210	18
967	Roles of the Hedgehog Signaling Pathway in Epidermal and Hair Follicle Development, Homeostasis, and Cancer. 2017 , 5,	45
966	Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor. 2017 , 9,	9
965	Transcription Factors in Breast Cancer-Lessons From Recent Genomic Analyses and Therapeutic Implications. 2017 , 107, 223-273	10
964	Cancer as a Paradigm for Translational and Clinical Biomedical Research. 2017 , 587-607	
963	Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia. 2017 , 7, 241	16
962	Modeling and Targeting MYC Genes in Childhood Brain Tumors. 2017 , 8,	15
961	Role of MYC in B Cell Lymphomagenesis. 2017 , 8,	14
960	Epigenetic Strategies to Boost Cancer Immunotherapies. 2017 , 18,	22
959	A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. 2017 , 8, 1035	33
958	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. 2017 , 2017, 6096134	23
957	Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. 2017 , 6,	106
956	Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway. 2017 , 8, 106833-106843	10
955	The role of targeted therapy in the management of patients with AML. 2017 , 1, 2281-2294	38
954	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. 2017 , 57, 331-342	27
953	Clinical Epigenetics of Lung Cancer. 2017 , 97-133	3
952	Targeted Protein Degradation. 2017 , 301-334	4
951	Establishing a reliable framework for harnessing the creative power of the scientific crowd. 2017 , 15, e2001387	8

950	BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. 2017 , 7, 16	35
949	Small-Molecule Inhibitors of Protein-Protein Interactions. 2017 , 329-353	2
948	Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. 2017 , 8, 51621-51629	17
947	Opportunities for targeting gene regulatory factors in B-cell acute lymphoblastic leukemia. 2017 , 6, 57-59	
946	Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer. 2017 , 202-280	3
945	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. 2017 , 37, 641-650	6
944	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. 2018 , 16, 1843-1850	10
943	Depletion of Mediator Kinase Module Subunits Represses Superenhancer-Associated Genes in Colon Cancer Cells. 2018 , 38,	12
942	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. 2018 , 37, 2850-2862	38
941	Chemically induced proximity in biology and medicine. 2018 , 359,	145
940	Targeting MYC in multiple myeloma. 2018 , 32, 1295-1306	53
939	Targeting oncogenic Myc as a strategy for cancer treatment. 2018 , 3, 5	318
938	Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. 2018 , 293, 5808-5820	37
937	Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. 2018 , 150, 156-175	13
936	A mechanism for epigenetic control of DNA replication. 2018 , 32, 224-229	32
935	Synthesis of a novel fused pyrrolo-diazepine-based library with anti-cancer activity. 2018 , 59, 1513-1516	6
934	A Bioactive Trypanosoma cruzi Bromodomain Inhibitor from Chemically Engineered Extracts. 2018 , 20, 220-228	11
933	BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. 2018 , 104, 265-274	24

932	Treatment of uveal melanoma: where are we now?. 2018 , 10, 1758834018757175	136
931	Targeting Epigenetic Modifiers for Cancer Treatments. 2018 , 4, 193-201	
930	Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. 2018 , 419, 64-74	25
929	The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. 2018 , 37, 2687-2701	42
928	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. 2018 , 14, 405-412	125
927	YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. 2018 , 78, 3306-3320	71
926	Pathways from epigenomics and glycobiochemistry towards novel biomarkers of addiction and its radical cure. 2018 , 116, 10-21	13
925	Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. 2018 , 73, 299-305	20
924	Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. 2018 , 152, 542-559	15
923	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. 2018 , 61, 4317-4334	53
922	Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation. 2018 , 6, 8	21
921	Large-scale analysis of water stability in bromodomain binding pockets with grand canonical Monte Carlo. 2018 , 1,	38
920	Identifying Small-Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces. 2018 , 13, 1051-1057	6
919	An epi(c)genetic war: Pathogens, cancer and human genome. 2018 , 1869, 333-345	4
918	Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. 2018 , 151, 450-461	41
917	BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors. 2018 , 40, e1800007	15
916	SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. 2018 , 360, 800-805	147
915	Research progress of selective small molecule bromodomain-containing protein 9 inhibitors. 2018 , 10, 895-906	2

914	Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors. 2018 , 28, 1811-1816	7
913	Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. 2018 , 17, 811-822	35
912	Structural plasticity of the TDRD3 Tudor domain probed by a fragment screening hit. 2018 , 285, 2091-2103	8
911	BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo. 2018 , 154, 158-165	10
910	BET bromodomain proteins regulate enhancer function during adipogenesis. 2018 , 115, 2144-2149	45
909	BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis. 2018 , 9, 203	41
908	Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. 2018 , 421, 112-120	21
907	Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1. 2018 , 293, 5345-5359	21
906	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. 2018 , 22, 796-808	57
905	Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. 2018 , 118, 1216-1252	149
904	Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer. 2018 , 9, 262-267	9
903	BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange-like syndrome. 2018 , 50, 329-332	52
902	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. 2018 , 8, 458-477	67
901	Double duty: ZMYND8 in the DNA damage response and cancer. 2018 , 17, 414-420	15
900	Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation. 2018 , 34, 67-74	4
899	Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. 2018 , 19, 407-415	24
898	Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple). 2018 , 4, 180-188	19
897	Enhancer dysfunction in leukemia. 2018 , 131, 1795-1804	14

896	BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition. 2018 , 16, 580-586	29
895	Crosstalk between the RNA Methylation and Histone-Binding Activities of MePCE Regulates P-TEFb Activation on Chromatin. 2018 , 22, 1374-1383	14
894	Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. 2018 , 8, 998	23
893	A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. 2018 , 92,	23
892	The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. 2018 , 37, 1830-1844	53
891	Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition. 2018 , 9, 2452-2468	27
890	Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016). 2018 , 28, 281-297	90
889	The Expanding World of N-MYC-Driven Tumors. 2018 , 8, 150-163	105
888	BET Proteins as Targets for Anticancer Treatment. 2018 , 8, 24-36	215
887	Benefit of Apabetalone on Plasma Proteins in Renal Disease. 2018 , 3, 711-721	24
886	Super-enhancers define a proliferative PGC-1 β -expressing melanoma subgroup sensitive to BET inhibition. 2018 , 37, 512-521	25
885	A BET Bromodomain Inhibitor Suppresses Adiposity-Associated Malignant Transformation. 2018 , 11, 129-142	2
884	Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762. 2018 , 11, 143-156	16
883	The rocky road to personalized medicine in acute myeloid leukaemia. 2018 , 22, 1411-1427	15
882	Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. 2018 , 24, 176-185	72
881	BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms. 2018 , 33, 3-5	6
880	Overcoming the resistance mechanisms of Smoothened inhibitors. 2018 , 23, 704-710	27
879	Chemical Control of a CRISPR-Cas9 Acetyltransferase. 2018 , 13, 455-460	21

878	Targeting Aberrations in Non-Small Cell Lung Cancer with Osimertinib. 2018 , 24, 2594-2604	53
877	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. 2018 , 293, 2422-2437	48
876	Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer. 2018 , 17, 1554-1565	23
875	Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. 2018 , 173, 1398-1412.e22	226
874	Along the Central Dogma-Controlling Gene Expression with Small Molecules. 2018 , 87, 391-420	15
873	When fragments link: a bibliometric perspective on the development of fragment-based drug discovery. 2018 , 23, 1596-1609	24
872	Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. 2018 , 428, 160-172	24
871	Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective. 2018 , 61, 8504-8535	38
870	Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors. 2018 , 152, 264-273	15
869	Selective Antagonists of the Bronchiolar Epithelial NF- κ B-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation. 2018 , 23, 1138-1151	32
868	CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies. 2018 , 57, 446-451	35
867	Epigenetic Pharmacology. 2018 , 1551-1575	
866	Targeting of epigenetic regulators in neuroblastoma. 2018 , 50, 1-12	16
865	Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis. 2018 , 173, 260-274.e25	125
864	miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein. 2018 , 8, 4482	18
863	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. 2018 , 103, 939-948	14
862	The dTAG system for immediate and target-specific protein degradation. 2018 , 14, 431-441	295
861	Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. 2018 , 32, 2224-2239	53

860	Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites. 2018 , 8, 189-193	11
859	The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. 2018 , 81, 197-210	16
858	Inhibition of BET selectively eliminates undifferentiated pluripotent stem cells. 2018 , 63, 477-487	4
857	RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. 2018 , 9, 1163	73
856	Epigenetik [Grundlagen und klinische Bedeutung. 2018 ,	0
855	Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). 2018 , 61, 3037-3058	25
854	Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells. 2018 , 29, 429-439	4
853	Klinische Bedeutung der Epigenetik. 2018 , 25-44	
852	A transcription factor network represses gene expression in airway epithelial cells. 2018 , 475, 1323-1334	18
851	The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. 2018 , 149, 575-584	63
850	The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators. 2018 , 293, 7160-7175	23
849	Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration. 2018 , 188, 1389-1405	6
848	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. 2018 , 33, 401-416.e8	138
847	Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. 2018 , 33, 512-526.e8	141
846	Biological function and histone recognition of family IV bromodomain-containing proteins. 2018 , 233, 1877-1886	31
845	Autofluorescence imaging identifies tumor cell-cycle status on a single-cell level. 2018 , 11, e201600276	21
844	DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis. 2017 , 8, e2552	23
843	Discovery of a Small-Molecule Degradator of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. 2018 , 61, 462-481	197

842	A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. 2018 , 61, 453-461	85
841	Bromodomain-containing proteins in prostate cancer. 2018 , 462, 31-40	17
840	Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. 2018 , 61, 504-513	107
839	Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. 2018 , 36, 85-95	16
838	Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. 2018 , 42, 106-113	26
837	Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development. 2018 , 31, 241-252	13
836	Modulators of 14-3-3 Protein-Protein Interactions. 2018 , 61, 3755-3778	121
835	Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. 2018 , 31, 253-266	7
834	Super enhancers - new analyses and perspectives on the low hanging fruit. 2018 , 9, 123-130	7
833	Targeting Epigenetics in Cancer. 2018 , 58, 187-207	128
832	How to effectively treat acute leukemia patients bearing MLL-rearrangements ?. 2018 , 147, 183-190	15
831	Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. 2018 , 23, 76-89	31
830	Epigenetic Events in Lung Cancer: Chromatin Remodeling and DNA Methylation. 2018 , 104-116.e5	1
829	Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. 2018 , 58, 209-229	15
828	JQ1 reduces Epstein-Barr virus-associated lymphoproliferative disease in mice without sustained oncogene repression. 2018 , 59, 1248-1251	3
827	Interactions between Retroviruses and the Host Cell Genome. 2018 , 8, 31-41	38
826	Vitamin C Sensitizes Melanoma to BET Inhibitors. 2018 , 78, 572-583	35
825	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. 2018 , 131, 771-781	33

824	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. 2018 , 33, 29-43.e7	113
823	Differentiation therapy revisited. 2018 , 18, 117-127	190
822	Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors. 2018 , 41, 46-56	3
821	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. 2018 , 26, 25-36	18
820	Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. 2018 , 131, 328-341	91
819	JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma. 2018 , 17, 107-118	21
818	ATAD2 in cancer: a pharmacologically challenging but tractable target. 2018 , 22, 85-96	24
817	Targeting bromodomain and extraterminal proteins in breast cancer. 2018 , 129, 156-176	26
816	Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all. 2018 , 195, 48-61	18
815	Chemical Biology Approaches for Investigating the Functions of Lysine Acetyltransferases. 2018 , 57, 1162-1184	16
814	Untersuchung der epigenetischen Funktionen von Lysin-Acetyltransferasen mit Methoden der chemischen Biologie. 2018 , 130, 1176-1199	0
813	What Is the BET on Solid Tumors?. 2018 , 36, 3040-3042	6
812	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. 2018 , 36, 3007-3014	116
811	Pharmacological inhibition of aberrant transcription factor complexes in inversion 16 acute myeloid leukemia. 2018 , 5, 30	1
810	Large-Scale Screening of Natural Products Transactivating Peroxisome Proliferator-Activated Receptor β Identifies 9S-Hydroxy-10E,12Z,15Z-Octadecatrienoic Acid and Cymarin as Potential Compounds Capable of Increasing Apolipoprotein A-I Transcription in Human Liver Cells. 2018 , 53, 1021-1030	4
809	Chromatin Dynamics in Cancer: Epigenetic Parameters and Cellular Fate—Histone Variants and Their Chaperones: New Targets?. 2018 , 372-372	
808	B-cell lymphoma 2 ovarian killer suppresses testicular cancer cell malignant behavior, but plays a role in platinum resistance. 2018 , 29, 839-846	3
807	Strategies targeting cellular senescence. 2018 , 128, 1247-1254	102

806	Structure-Based Approach toward Identification of Inhibitory Fragments for Eleven-Nineteen-Leukemia Protein (ENL). 2018 , 61, 10929-10934	20
805	Step II: Target Validation. 2018 , 33-76	
804	(+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NFB signaling. 2018 , 8, 60	22
803	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. 2018 , 34, 982-995.e7	58
802	BRD4 expression in patients with essential hypertension and its effect on blood pressure in spontaneously hypertensive rats. 2018 , 12, e107-e117	6
801	BRD4 and Cancer: going beyond transcriptional regulation. 2018 , 17, 164	191
800	Specific MHC-I Peptides Are Induced Using PROTACs. 2018 , 9, 2697	24
799	HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. 2018 , 215, 3194-3212	21
798	Drug target prediction using chem- and bioinformatics. 2018 , 3,	1
797	Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. 2018 , 9, 4931	72
796	Brd4's Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1. 2018 , 25, 1756-1771	41
795	Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma. 2018 , 7, 83	4
794	In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1. 2018 , 29, 975-996	7
793	Epigenetic Therapy. 2018 , 1-1	0
792	Mod Squad: Altered Histone Modifications in Cancer. 2018 , 481-481	
791	Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets. 2018 , 19, 216	12
790	Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases. 2018 , 4, e000744	30
789	BRD4 interacts with PML/RAR α in acute promyelocytic leukemia. 2018 , 12, 726-734	1

788	Drug and disease signature integration identifies synergistic combinations in glioblastoma. 2018 , 9, 5315	44
787	Characterizing Molecular Adsorption on Biodegradable MnO ₂ Nanoscaffolds. 2018 , 122, 29017-29027	8
786	A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. 2018 , 9, 5139	67
785	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. 2018 , 34, 922-938.e7	31
784	Bromodomain Drug Discovery - the Past, the Present, and the Future. 2018 , 18, 1808-1817	62
783	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. 2018 , 72, 341-354.e6	38
782	Mediator and RNA polymerase II clusters associate in transcription-dependent condensates. 2018 , 361, 412-415	583
781	Genome-Informed Targeted Therapy for Osteosarcoma. 2019 , 9, 46-63	130
780	HIV latency reversing agents act through Tat post translational modifications. 2018 , 15, 36	18
779	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. 2018 , 109, 3602-3610	11
778	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. 2018 , 43, 1014-1032	86
777	Discovery of an MLLT1/3 YEATS Domain Chemical Probe. 2018 , 57, 16302-16307	32
776	Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. 2018 , 61, 9316-9334	42
775	Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer. 2018 , 23, 223-235	15
774	NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment. 2018 , 68, 583-595	90
773	A Comparative Study of Fluorescence Assays in Screening for BRD4. 2018 , 16, 372-383	2
772	[Genomic characterization of head and neck squamous cell carcinoma: Impact and challenges for therapeutic management]. 2018 , 105, 820-829	0
771	Novel treatments to tackle myelofibrosis. 2018 , 11, 889-902	1

770	Mapping the Ligand Binding Landscape. 2018 , 115, 1707-1719	22
769	Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy. 2018 , 175, 766-779.e17	53
768	Entdeckung einer chemischen Sonde für MLLT1/3-YEATS-Domänen. 2018 , 130, 16540-16545	1
767	Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe. 2018 , 9, 1223-1229	3
766	Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. 2018 , 24, 1599-1610	142
765	Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. 2018 , 8, 13225	19
764	Human Bone Marrow Mesenchymal Stem Cells Promote Gastric Cancer Growth via Regulating. 2018 , 2018, 9501747	18
763	The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines. 2021 , 67, 83-94	
762	Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. 2021 , 222, 113588	6
761	Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities. 2021 , 173, 105901	3
760	Bromodomains: A novel target for the anticancer therapy. 2021 , 911, 174523	2
759	Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread. 2021 , 223, 113601	2
758	Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins. 2021 , 226, 113853	2
757	The transcriptional stress response and its implications in cancer treatment. 2021 , 1876, 188620	0
756	Epigenetic regulator BRD4 is involved in cadmium-induced acute kidney injury via contributing to lysosomal dysfunction, autophagy blockade and oxidative stress. 2022 , 423, 127110	12
755	Epigenetics and Cancer. 2021 , 151-177	0
754	BET bromodomain inhibitors regulate keratinocyte plasticity. 2021 , 17, 280-290	6
753	Epigenetics in toxicology and drug development. 2021 , 529-558	

752	Deciphering the PTM codes of the tumor suppressor p53. 2021 ,	4
751	BRD4-mediated repression of p53 is a target for combination therapy in AML. 2021 , 12, 241	11
750	Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. 2020 , 11, 621093	20
749	Design, Synthesis and Activity Evaluation of Novel Bromodomain-Containing Protein 4 (BRD4) Small Molecule Inhibitor Based on ABBV-075. 2021 , 41, 1712	
748	Functions of MicroRNA Methylations in Cancer: From Bench to Bedside. 2021 , 527-553	
747	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. 2021 , 81, 1627-1632	7
746	BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis. 2021 ,	0
745	Supercharging BRD4 with NUT in carcinoma. 2021 , 40, 1396-1408	10
744	Epigenetic Regulation in Breast Cancer. 2021 , 1187, 103-119	1
743	Targeting MYCN in Molecularly Defined Malignant Brain Tumors. 2020 , 10, 626751	5
742	Neuroblastoma: Current advancements and future therapeutics. 2021 , 281-297	1
741	Enzyme-responsive micellar JQ1 induces enhanced BET protein inhibition and immunotherapy of malignant tumors. 2021 , 9, 6915-6926	4
740	Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure. 2021 , 18, 3	3
739	Chemogenomics for drug discovery: clinical molecules from open access chemical probes. 2021 , 2, 759-795	2
738	Structural Genomics and Drug Discovery for Chromatin-Related Protein Complexes Involved in Histone Tail Recognition. 2014 , 211-225	1
737	Exploring Chromatin Readers Using High-Accuracy Quantitative Mass Spectrometry-Based Proteomics. 2014 , 133-148	2
736	Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology. 2014 , 279-298	2
735	Regulating Chromatin by Histone Acetylation. 2014 , 147-212	18

734	Structural genomics of human proteins. 2014 , 1140, 27-34	1
733	Overview of chemical genomics and proteomics. 2012 , 800, 3-10	6
732	A Toolbox for the Identification of Modes of Action of Natural Products. 2019 , 110, 73-97	2
731	Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses. 2020 , 1202, 259-279	8
730	Epigenetic Control Using Small Molecules in Cancer. 2020 , 111-148	1
729	Anti-inflammatory Effects of BET Protein Inhibition Through Modulation of Gene Transcription. 2015 , 199-223	1
728	BET Bromodomain Inhibition as a Therapeutic Approach in Hematological Malignancies. 2015 , 185-198	1
727	Cellular and Molecular Basis of KMT2A/MLL Leukaemias: From Transformation Mechanisms to Novel Therapeutic Strategies. 2015 , 223-250	2
726	Brainstem Tumors. 2019 , 1-35	1
725	Regulation of Stem Cells by Cullin-RING Ligase. 2020 , 1217, 79-98	2
724	Overview of Histone Modification. 2021 , 1283, 1-16	31
723	Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders. 2017 , 54, 4466-4476	24
722	HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report. 2020 , 14, 1117-1122	7
721	Novel Therapeutics Targeting Epigenetics. 2017 , 297-328	1
720	The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells. 2020 , 486, 46-57	10
719	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. 2020 , 78, 1096-1113.e8	35
718	Opposing Functions of BRD4 Isoforms in Breast Cancer. 2020 , 78, 1114-1132.e10	35
717	Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112. 2016 , 55, 3727-34	35

716	Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain. 2017 , 13, 3260-3275	26
715	Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel-Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay. 2021 , 6, 680-695	5
714	Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. 2017 , 13, 850-857	56
713	Consortium solves its 1,000th protein structure. <i>Nature</i> , 50.4	1
712	Chromatin dependencies in cancer and inflammation. 2018 , 19, 245-261	36
711	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. 2020 , 123, 1730-1736	26
710	The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice. 2017 , 7, e1239	40
709	CHAPTER 11:Histone Methyltransferase Activity Assays. 2015 , 267-287	2
708	CHAPTER 12:Safety Considerations for Epigenetic Mechanisms as Drug Targets: Are Existing Toxicology Studies Fit for Purpose?. 2015 , 288-315	1
707	Novel pyrano 1,3 oxazine based ligand inhibits the epigenetic reader hBRD2 in glioblastoma. 2020 , 477, 2263-2279	3
706	Multiple P-TEFbs cooperatively regulate the release of promoter-proximally paused RNA polymerase II. 2016 , 44, 6853-67	56
705	Metastatic NUT Midline Carcinoma Treated With Aggressive Neoadjuvant Chemotherapy, Radiation, and Resection: A Case Report and Review of the Literature. 2021 , 43, e73-e75	1
704	NUT Carcinoma Without Upfront Surgical Resection: A Case Report. 2021 , 43, e707-e710	1
703	Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells. 2017 , 98, 799-809	10
702	Reinvestigating the role of ERK5: kinase activity is not required for cellular immune response or proliferation.	2
701	Predicting binding free energies: Frontiers and benchmarks.	4
700	BRD4 inhibitors block telomere elongation.	1
699	Selective and mechanistic sources of recurrent rearrangements across the cancer genome.	20

698	Bromodomain inhibition reveals FGF15/19 as a target of epigenetic regulation and metabolic control.	2
697	Rationalizing PROTAC-mediated ternary complex formation using Rosetta.	5
696	BAZ2A association with H3K14ac is required for the transition of prostate cancer cells into a cancer stem-like state.	0
695	A Transcriptional Switch Governing Fibroblast Plasticity Underlies Reversibility of Chronic Heart Disease.	2
694	Inhibition of histone readers bromodomain extra-terminal proteins alleviates scleroderma fibrosis.	1
693	Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical).	1
692	TNF stimulation primarily modulates transcriptional burst size of NF- κ B-regulated genes.	1
691	EcDNA hubs drive cooperative intermolecular oncogene expression.	3
690	Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response.	1
689	Chromatin Functional States Correlate with HIV Latency Reversal in Infected Primary CD4+T cells.	2
688	USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia.	1
687	Mapping the ligand binding landscape.	1
686	Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.	1
685	Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.	1
684	A structure-based approach towards identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL) YEATS domain.	1
683	Loci specific epigenetic drug sensitivity.	1
682	Nucleosome scaffolding by Brd4 tandem bromodomains in acetylation-dependent chromatin compartmentalization.	2
681	Biological Plasticity Rescues Target Activity in CRISPR Knockouts.	4

680	Integrated single cell and bulk multi-omics reveals heterogeneity and early changes in pathways associated with cetuximab resistance in HNSCC sensitive cell lines.	2
679	Essentiality of CREBBP in EP300 truncated B-cell lymphoma revealed by genome-wide CRISPR-Cas9 screen.	1
678	GeneWalk identifies relevant gene functions for a biological context using network representation learning.	4
677	Native mass spectrometry can effectively predict PROTAC efficacy.	3
676	BRD4 Prevents R-Loop Formation and Transcription-Replication Conflicts by Ensuring Efficient Transcription Elongation.	2
675	Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. 2017 , 27, 1830-1842	40
674	Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. 2021 , 106, 90-99	11
673	MYC and Chromatin. 2015 , 3,	3
672	Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice. 2020 , 5,	20
671	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. 2020 , 5,	12
670	BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination. 2020 , 6,	5
669	BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. 2017 , 2, e88032	34
668	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. 2019 , 129, 3361-3373	35
667	BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. 2019 , 129, 1878-1894	27
666	Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. 2020 , 130, 1782-1792	15
665	Tendon-derived cathepsin K-expressing progenitor cells activate Hedgehog signaling to drive heterotopic ossification. 2020 , 130, 6354-6365	14
664	BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice. 2020 , 130, 4740-4758	12
663	BETs that cover the spread from acquired to heritable heart failure. 2020 , 130, 4536-4539	1

662	Cancer epigenetics drug discovery and development: the challenge of hitting the mark. 2014 , 124, 64-9	117
661	CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. 2016 , 126, 639-52	147
660	Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. 2016 , 126, 4237-4249	28
659	ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis. 2018 , 128, 1937-1955	64
658	Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology. 2019 , 8,	12
657	Strategically targeting MYC in cancer. 2016 , 5,	63
656	Recent advances in targeted therapy for Ewing sarcoma. 2016 , 5,	37
655	Histone modifications and a choice of variant: a language that helps the genome express itself. 2014 , 6, 76	38
654	Keap1-Independent Regulation of Nrf2 Activity by Protein Acetylation and a BET Bromodomain Protein. 2016 , 12, e1006072	21
653	Epigenetics in Cancer: A Hematological Perspective. 2016 , 12, e1006193	55
652	Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer. 2016 , 12, e1006272	71
651	BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. 2013 , 8, e72967	136
650	Analysis of the papillomavirus E2 and bromodomain protein Brd4 interaction using bimolecular fluorescence complementation. 2013 , 8, e77994	14
649	Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. 2014 , 9, e87003	45
648	BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β Cell. 2016 , 11, e0151329	48
647	A Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the Complex. 2016 , 11, e0156344	8
646	Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability. 2016 , 11, e0159180	14
645	MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development. 2017 , 12, e0170339	3

644	BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells. 2017 , 12, e0189102	9
643	Papillomavirus-Associated Tumor Formation Critically Depends on c-Fos Expression Induced by Viral Protein E2 and Bromodomain Protein Brd4. 2016 , 12, e1005366	22
642	An Epigenetic Compound Library Screen Identifies BET Inhibitors That Promote HSV-1 and -2 Replication by Bridging P-TEFb to Viral Gene Promoters through BRD4. 2016 , 12, e1005950	18
641	BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency. 2017 , 13, e1006100	24
640	PCAF, ISX, and BRD4: a maleficent alliance serving lung cancer malignancy. 2020 , 21, e49766	4
639	LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma. 2020 , 12, e12525	16
638	The Bromodomain Inhibitor JQ1 Enhances the Responses to All- Retinoic Acid in HL-60 and MV4-11 Leukemia Cells. 2018 , 11, 131-140	8
637	Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer. 2019 , 26, R211-R235	13
636	Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. 2020 , 27, 163-174	3
635	Different Mechanisms of Epigenetic Regulation of Gene Expression. 2015 , 2,	3
634	Targeting Epigenetic 'Readers' with Natural Compounds for Cancer Interception. 2020 , 25, 189-203	3
633	The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion. 2020 , 12, 397-415	6
632	BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma. 2020 , 12, 17541-17567	4
631	Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. 2016 , 7, 57327-57350	23
630	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. 2016 , 7, 61469-61484	49
629	JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer. 2016 , 7, 66809-66821	34
628	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. 2016 , 7, 72395-72414	19
627	Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. 2016 , 7, 69291-69308	19

626	Proteomic analysis reveals diverse proline hydroxylation-mediated oxygen-sensing cellular pathways in cancer cells. 2016 , 7, 79154-79169	15
625	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. 2016 , 7, 79217-79232	14
624	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. 2013 , 4, 2080-95	97
623	Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. 2017 , 8, 28922-28938	13
622	BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. 2017 , 8, 29558-29573	29
621	BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). 2017 , 8, 51402-51415	16
620	Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. 2014 , 5, 3168-72	50
619	Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. 2014 , 5, 2016-29	91
618	BET inhibitors as novel therapeutic agents in breast cancer. 2017 , 8, 71285-71291	27
617	Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. 2014 , 5, 4257-68	24
616	JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against -amplified small cell lung cancer. 2017 , 8, 86312-86324	28
615	Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth. 2017 , 8, 98471-98481	20
614	The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells. 2017 , 8, 94104-94116	4
613	Molecular-genetic profiling and high-throughput drug screening in NUT midline carcinoma-an aggressive and fatal disease. 2017 , 8, 112313-112329	19
612	Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. 2018 , 9, 23003-23017	17
611	Combined HAT/EZH2 modulation leads to cancer-selective cell death. 2018 , 9, 25630-25646	5
610	Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. 2018 , 9, 26491-26506	13
609	BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. 2018 , 9, 29193-29207	27

608	Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells. 2018 , 9, 33853-33864	7
607	BET inhibitors: Betting on improved outcomes in uterine serous carcinoma. 2018 , 9, 35470-35471	2
606	The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors. 2019 , 10, 2151-2160	9
605	Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. 2015 , 6, 2407-20	45
604	The histone code reader SPIN1 controls RET signaling in liposarcoma. 2015 , 6, 4773-89	41
603	JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. 2015 , 6, 6915-30	64
602	Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. 2015 , 6, 18921-32	41
601	Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion. 2015 , 6, 15857-70	25
600	BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutant uveal melanoma cells. 2015 , 6, 33397-409	42
599	MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. 2015 , 6, 38591-616	35
598	The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. 2015 , 6, 34669-79	33
597	Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. 2016 , 7, 6576-92	28
596	Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. 2015 , 6, 32380-95	35
595	Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. 2016 , 7, 2462-74	68
594	Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. 2016 , 7, 1451-63	41
593	High level of BRD4 promotes non-small cell lung cancer progression. 2016 , 7, 9491-500	33
592	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. 2016 , 7, 35753-35767	37
591	FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways. 2016 , 7, 42792-42804	37

590	Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer. 2016 , 7, 32628-40	38
589	BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. 2016 , 7, 38319-38332	36
588	Targeting BET bromodomain proteins in solid tumors. 2016 , 7, 53997-54009	74
587	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. 2016 , 7, 40690-40703	11
586	Nitric oxide-elicited resistance to anti-glioblastoma photodynamic therapy. 2020 , 3, 401-414	3
585	Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer. 2017 , 5, 372	3
584	Targeting BRD9 for Cancer Treatment: A New Strategy. 2020 , 13, 13191-13200	2
583	Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics. 2015 , 22, 4033-57	7
582	Aim for the Readers! Bromodomains As New Targets Against Chagas' Disease. 2019 , 26, 6544-6563	2
581	Twist-BRD4 complex: potential drug target for basal-like breast cancer. 2015 , 21, 1256-61	19
580	Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. 2019 , 25, 635-641	7
579	Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. 2016 , 16, 697-713	21
578	Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. 2018 , 16, 1045-1058	20
577	Bromodomain-Containing Protein 4: A Druggable Target. 2019 , 20, 1517-1536	3
576	The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner. 2020 , 20, 1613-1625	6
575	Drug discovery toward antagonists of methyl-lysine binding proteins. 2011 , 5, 51-61	29
574	Methods for Activity Analysis of the Proteins that Regulate Histone Methylation. 2011 , 5, 95-105	11
573	Manipulation of the host protein acetylation network by human immunodeficiency virus type 1. 2015 , 50, 314-25	15

572	The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer. 2020 , 13,	4
571	Synthesis of Biologically Active Molecules through Multicomponent Reactions. 2020 , 25,	64
570	Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. 2016 , 22, 7938-50	49
569	General mechanism of JQ1 in inhibiting various types of cancer. 2020 , 21, 1021-1034	13
568	BET Bromodomain Inhibition Suppresses Human T Cell Function. 2019 , 3, 294-305	12
567	Prostate cancer epigenetics and its clinical implications. 2016 , 18, 549-58	23
566	Regulation of MYC gene expression by aberrant Wnt/ β -catenin signaling in colorectal cancer. 2015 , 6, 290-300	82
565	JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF- κ B axis. 2017 , 50, 640-646	15
564	Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. 2015 , 4, e07072	15
563	Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. 2017 , 6,	28
562	BRD3-NUTM1-expressing NUT carcinoma of lung on endobronchial ultrasound-guided transbronchial needle aspiration cytology, a diagnostic pitfall. 2021 , 50, E47	0
561	Domain-selective BET inhibition attenuates transcriptional and behavioral responses to cocaine.	
560	Prognostic Significance of Dysregulated Epigenomic and Chromatin Modifiers in Cervical Cancer. 2021 , 10,	1
559	Vpr shapes the proviral landscape and polyclonal HIV-1 reactivation patterns in cultured cells.	
558	Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. 2021 ,	4
557	Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. 2021 , 17, 1157-1167	14
556	Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins. 2021 , 64, 15477-15502	5
555	Brd4 is required for chondrocyte differentiation and endochondral ossification. 2022 , 154, 116234	0

554	BET Proteins as Attractive Targets for Cancer Therapeutics. 2021 , 22,	3
553	Effect of N-Vinyl-2-Pyrrolidone (NVP), a Bromodomain-Binding Small Chemical, on Osteoblast and Osteoclast Differentiation and Its Potential Application for Bone Regeneration. 2021 , 22,	1
552	Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. 2021 , 12, 6060	2
551	Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy. 2021 , 8, e2101999	5
550	BRD4 orchestrates genome folding to promote neural crest differentiation. 2021 , 53, 1480-1492	4
549	The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation. 2021 , 13,	2
548	Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity. 2021 , 24, 103323	1
547	Atomistic insights into the selective therapeutic activity of 6-(2,4-difluorophenoxy)-5-((ethylmethyl)pyridine-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one towards bromodomain-containing proteins. 2021 , 95, 107592	
546	Modulation of Developmentally Regulated Gene Expression Programs through Targeting of Polycomb and Trithorax Group Proteins. 511-538	1
545	Front Matter. I-XXI	
544	Evaluating Chromatin Regulators in Cancer Cell Lines Through RNAi-Glasses. 2014 , 297-308	
543	Epigenetics of Host-Pathogen Interactions: The Road Ahead and the Road Behind. 2013 , 25-46	
542	A Case of NUT Midline Carcinoma of the Lung. 2015 , 55, 1080-1085	2
541	Activating Latent HIV by Inhibiting Bromodomain Proteins. 2015 , 225-241	
540	CHAPTER 10:Fragment-Based Approaches to Epigenetic Targets. 2015 , 238-258	
539	Epigenetic Drug Discovery. 2015 , 27-40	
538	CHAPTER 8:Progress in Targeting Epigenetic Readers. 2015 , 192-229	
537	CHAPTER 9:Who will Benefit from Epigenetic Drugs?. 2015 , 230-248	

- 536 Epigenomic Measurements in Brain Tissues. **2015**, 1-41
- 535 CHAPTER 10:Dosing ¶When Less is More. **2015**, 249-266
- 534 Epigenomic Measurements in Brain Tissues. **2016**, 2857-2897
- 533 Protein Lysine Acetylated/Deacetylated Enzymes and the Metabolism-Related Diseases. **2016**, 07, 454-467 1
- 532 Chromatin Remodeling in Heart Failure. **2016**, 103-124
- 531 BET Bromodomains and P-TEFb in Cardiac Transcription and Heart Failure Pathogenesis. **2016**, 283-296
- 530 How the AFF1/4 scaffold recruits the elongation factor ELL2 to promote HIV-1 proviral transcription.
- 529 Flow Cytometric Analysis of Drug-induced HIV-1 Transcriptional Activity in A2 and A72 J-Lat Cell Lines. **2017**, 7, 1
- 528 Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines. **2017**, 7,
- 527 Development of N6-(Heteroarylcarbonyl)adenines as BRD4 Inhibitors. **2017**, 94, 1107 0
- 526 Epigenetic Reprogramming of Tissue-Specific Transcription Promotes Metastasis.
- 525 JQ1 reduces Epstein-Barr virus-associated lymphoproliferative disease in mice without sustained oncogene repression.
- 524 Chemical control of a CRISPR-Cas9 acetyltransferase.
- 523 Brd4-bound enhancers drive cell intrinsic sex differences in glioblastoma.
- 522 JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
- 521 LncRNA Interpreter: A Protein-Centric Pipeline for Mechanistic Analysis of Long Noncoding RNAs.
- 520 BET Bromodomain Targeting Suppresses the PD-1/PD-L1 Pathway in Triple-negative Breast Cancer and Elicits Anti-tumor Immune Response. 1
- 519 Signaling Landscape of AML: The Story So Far. **2018**, 233-262

- 518 Spatially clustered loci with multiple enhancers are frequent targets of HIV-1. 0
- 517 Identifying small molecule binding sites for epigenetic proteins at domain-domain interfaces.
- 516 Studying Stimulus-Induced Changes in RNA Dynamics by Mutational Mapping through TimeLapse-seq. **2018**, 32, lb23
- 515 MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphoma.
- 514 Multiple myeloma immunoglobulin κ translocations portend poor prognosis. 1
- 513 A Chemical Toolbox for the Study of Bromodomains and Epigenetic Signaling.
- 512 DOT1L inhibition reveals a distinct class of enhancers dependent on H3K79 methylation. 0
- 511 In silico results of μ -Opioid receptor antagonists as ligands for the second bromodomain of the Pleckstrin Homology Domain Interacting Protein.
- 510 MTHFD1 is a genetic interactor of BRD4 and links folate metabolism to transcriptional regulation.
- 509 Targeting MYC Overexpressing Leukemia with Cardiac Glycoside Proscillaridin Through Downregulation of Histone Acetyltransferases. 0
- 508 Development of Practical Artificial Intelligence System for Drug Discovery and Its Application to Activity Prediction of Small Molecule Protein-Protein Interaction Modulators. **2019**, 19, 5-10 1
- 507 Defining CBX7-Dependent Chromatin Architecture with Rapid Small-Molecule Inhibition.
- 506 Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance. **2019**, 217-232
- 505 Developing BET-ter treatments for cutaneous T-cell lymphoma. **2019**, 10, 1267-1268
- 504 Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation.
- 503 Cohesin occupancy and composition at enhancers and promoters are linked to DNA replication origin proximity in *Drosophila*.
- 502 A non-canonical role and regulations of polo-like kinase-4 in fibroblast cell-type transition.
- 501 The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets. 0

500 Plasmablastic Lymphoma and Primary Effusion Lymphoma. **2020**, 101-118

499 A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis. **2019**, 39,

498 Cyclic peptides can engage a single binding pocket through multiple, entirely divergent modes.

0

497 TP63, SOX2 and KLF5 Establish Core Regulatory Circuitry and Construct Cancer Specific Epigenome in Esophageal Squamous Cell Carcinoma.

1

496 MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. **2020**, 19, 1418-1426

5

495 Ameliorative effect of a quinazoline-based bromodomain inhibitor, CN210, on experimentally-induced Crohn's disease-like murine ileitis via inhibition of inflammatory cytokine expression.

494 Brainstem Tumors. **2020**, 1957-1983

493 Chapter 6:Structure-based PROTAC Design. **2020**, 115-134

492 Modulating Epigenetic Modification Enzymes Through Relevant Epidrugs as a Timely Strategy in Anticancer Therapy. **2020**, 137-157

491 BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma.

490 Differential activation of P-TEFb complexes in the development of cardiomyocyte hypertrophy following activation of distinct GPCRs.

489 Mouse tumor susceptibility genes identify drug combinations for multiple myeloma. **2020**, 6,

0

488 A targetable epigenetic vulnerability in PI3K/AKT inhibitor resistant cancers.

487 A Strategy to Assess the Cellular Activity of E3 Ligases against Neo-Substrates using Electrophilic Probes.

486 Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins. **2020**, 7, 198

3

485 In Silico Analysis of Protein-Protein Interactions Between Estrogen Receptor and Fungal Laccase. **2021**, 737-747

1

484 BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma. **2021**, 12, 1020

1

483 JQ1 attenuates psychostimulant- but not opioid-induced conditioned place preference. **2022**, 418, 113644

2

482	Genetic Code Expansion Tools to Study Lysine Acylation. 2021 , 5, e2100926	3
481	Enabling cancer target validation with genetically encoded systems for ligand-induced protein degradation. 2021 , 1, 100011	0
480	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. 2021 ,	4
479	The Klf6 Super-enhancer Determines Klf6 Sensitivity to BRD4 Inhibitors in Human Hepatoma (HepG2) Cells. 2020 , 9, 209-218	1
478	Nuclear protein in testis (NUT) carcinoma in the public sector of the Free State province, South Africa. 4,	
477	Negative effects of tumor cell nitric oxide on anti-glioblastoma photodynamic therapy. 2020 , 6,	0
476	Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy. 2022 , 227, 113953	1
475	Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal molecular mechanisms of oncogenesis and intrinsic drug resistance.	
474	The Role of Epigenetics in Type 1 Diabetes. 2020 , 1253, 223-257	5
473	CHAPTER 11:Chemical Probes in Cellular Assays for Target Validation and Screening in Neurodegeneration. 2020 , 276-319	
472	BET mechanisms in cancer. 2020 , 101-142	
471	CHAPTER 9:Pharmacological Regulation and Functional Significance of Chromatin Binding by BET Tandem Bromodomains. 2020 , 209-248	
470	Pathology of Thymic Carcinoma. 2020 , 123-139	
469	BET Bromodomain Proteins Regulate Transcriptional Reprogramming in Genetic Dilated Cardiomyopathy.	2
468	Drug Discovery of Acetophenone Derivatives as BRD4 Inhibitors. 2020 , 17, 323-329	
467	BRD4 Interacts with GATA4 to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes.	1
466	Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins. 2021 , 4, 1273	3
465	Genetic Landscape and Emerging Therapies in Uveal Melanoma. 2021 , 13,	6

- 464 Inhibition of BET family proteins suppresses African swine fever virus infection.
- 463 -Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review.. **2021**, 28, 4485-4503 2
- 462 Biomimetic and responsive nanoparticles loading JQ1 for dual-targeting treatment of vascular restenosis via multiple actions. **2021**, 133452 1
- 461 KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma.
- 460 Viral mimicry of p65/RelA transactivation domain to inhibit NF- κ B activation.
- 459 BRD4-mediated repression of p53 is a target for combination therapy in AML.
- 458 Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. **2010**, 10, 489-99 50
- 457 Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder. **2014**, 7, 4231-8 9
- 456 Epigenetics and chromatin remodeling play a role in lung disease. **2011**, 10, 7-16 21
- 455 The converging roles of BRD4 and gene transcription in pluripotency and oncogenesis. **2015**, 2, 1
- 454 Epigenetic intervention with a BET inhibitor ameliorates acute retinal ganglion cell death in mice. **2017**, 23, 149-159 8
- 453 Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. **2017**, 7, 1724-1737 7
- 452 EPIGENETIC MECHANISMS IN MULTIPLE SCLEROSIS. **2014**, 6, 25-35 2
- 451 Therapeutic targeting of immune checkpoints with small molecule inhibitors. **2019**, 11, 529-541 8
- 450 FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression. **2020**, 10, 523-535 4
- 449 SPOP and cancer: a systematic review. **2020**, 10, 704-726 14
- 448 [Histone modification aberrations in acute myeloid leukemia and the target therapy development in clinical settings]. **2018**, 39, 171-176
- 447 [Mechanism of action of BET bromodomain inhibitor JQ1 in treating airway remodeling in asthmatic mice]. **2017**, 19, 1278-1284

446	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. 2021 , 11, 530-545	2
445	Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer. 2021 , 11, 3021-3038	1
444	Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells. 2021 , 53, 116533	
443	A synergistic multitargeted of BET and HDAC: an intra-molecular mechanism of communication in treatment of Waldenström macroglobulinemia. 1-12	1
442	Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer.. 2022 , 38, 11-19	0
441	Protein lysine acetylation and its role in different human pathologies: a proteomic approach. 2021 , 1-27	1
440	Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. 2021 , 44, 1387-1403	0
439	Epigenetic changes in autoimmune monocytes contribute to disease and can be targeted by JAK inhibition.	
438	ecDNA hubs drive cooperative intermolecular oncogene expression. <i>Nature</i> , 2021 ,	50.4 18
437	The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. 2021 , 20, 145	3
436	Theoretically exploring selective-binding mechanisms of BRD4 through integrative computational approaches. 2021 , 32, 985-1011	2
435	Novel therapeutics and targets in myelofibrosis. 2021 , 1-14	1
434	The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. 2021 , 11, 23370	2
433	KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth. 2021 , 4, 1330	0
432	Preclinical Evaluation of a Novel Dual Targeting PI3K/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia.. 2021 , 11, 766888	0
431	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.. 2022 ,	0
430	Now open: Evolving insights to the roles of lysine acetylation in chromatin organization and function.. 2022 ,	2
429	Chromatin remodeling induced by ARID1A loss in lung cancer promotes glycolysis and confers JQ1 vulnerability.. 2022 ,	2

428	Genomic Identification, Evolution, and Expression Analysis of Bromodomain Genes Family in Buffalo.. 2022 , 13,	0
427	Functions and inhibition of BET bromodomains in pathogenic fungi. 2022 , 34, 100590	0
426	Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors.. 2021 , 55, 116592	0
425	Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.. 2021 , 24, 109-119	1
424	A role for BET proteins in regulating basal and dopamine-induced, cAMP/PKA dependent transcription in rat striatal neurons.. 2021 , 91, 110226	2
423	Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. 2021 ,	4
422	Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.. 2021 , 13,	1
421	BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2.. 2022 , 24, 24-34	5
420	JQ-1 ameliorates schistosomiasis liver granuloma in mice by suppressing male and female reproductive systems and egg development of Schistosoma japonicum.	
419	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.. 2022 , 119,	1
418	Epigenetic landscape of drug responses revealed through large-scale CHIP-seq data analyses.. 2022 , 23, 51	0
417	So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.. 2022 , 14,	0
416	Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation.	
415	Importance of Three-Body Problems and Protein-Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations.. 2022 ,	4
414	New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia. 2022 , 329-351	
413	Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.. 2022 ,	2
412	Cure and Long-Term Remission Strategies.. 2022 , 2407, 391-428	1
411	BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.. 2022 ,	2

410	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.. 2022 , 3, 2	0
409	Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials.. 2022 ,	0
408	Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy.. 2022 , 8, e08702	4
407	Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.. 2022 , 14, 75-89	0
406	Triple combination of BET plus PI3K and NF- κ B inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma.. 2022 ,	1
405	Role of Cardiac Fibroblasts in Cardiac Injury and Repair.. 2022 , 24, 295	1
404	Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma.. 2021 , 11, 773186	2
403	Bromodomain Inhibition Reveals FGF15/19 as a Target of Epigenetic Regulation and Metabolic Control.. 2022 ,	0
402	Evaluation of plant-derived semi-synthetic molecules against BRD3-BD2 protein: a computational strategy to combat breast cancer.	4
401	Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis.. 2022 , 15,	0
400	BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4.. 2022 , 119,	1
399	The deubiquitinating enzyme USP17 regulates c-Myc levels and controls cell proliferation and glycolysis.. 2022 ,	1
398	Targeting BET Bromodomains in Cancer. 2022 , 6,	0
397	A natural product targets BRD4 to inhibit phase separation and gene transcription.. 2022 , 25, 103719	0
396	Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.. 2022 , 171, 39-39	0
395	BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer.. 2022 , 119,	4
394	Virtual Screening of Antitumor Inhibitors Targeting BRD4 Based on Machine Learning Methods. 2022 , 7,	
393	A synthetic resveratrol analog termed Q205 reactivates latent HIV-1 through activation of P-TEFb.. 2021 , 114901	2

392	Discovery and Mechanism of Small Molecule Inhibitors Selective for the Chromatin-Binding Domains of Oncogenic UHRF1.. 2022,	2
391	Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.. 2022,	0
390	Recent Advances in Dual BRD4-Kinase Inhibitors Base on Polypharmacology.. 2022,	1
389	Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.. 2022,	0
388	MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion-positive lung cancer.. 2022,	1
387	The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.. 2022, 136, 197-222	4
386	The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma.. 2022, 22, 64	0
385	The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy.. 2022, 54, 107-114	1
384	Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents.. 2022, 58, 116653	1
383	Molecular mimicry of NF- κ B by vaccinia virus protein enables selective inhibition of antiviral responses.. 2021,	2
382	Conditional Human BRD4 Knock-In Transgenic Mouse Genotyping and Protein Isoform Detection.. 2022, 12,	
381	Photo-Brook rearrangement of acyl silanes as a strategy for photoaffinity probe design.. 2022, 13, 3851-3856	5
380	Lights on 2,5-diaryl tetrazoles: applications and limits of a versatile photoclick reaction.. 2022, 1	0
379	BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.. 2022,	0
378	Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?. 2022, 14,	0
377	Epigenetic Regulation: A Link between Inflammation and Carcinogenesis.. 2022, 14,	1
376	Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.. 2022, 78, 119-127	
375	Precision Medicine for \pm -Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.. 2022, 14,	0

374	Human expandable pancreatic progenitor-derived β cells ameliorate diabetes.. 2022 , 8, eabk1826	1
373	NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics.. 2022 , 12, 860830	0
372	The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.. 2022 , 14,	1
371	Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation.. 2022 ,	1
370	CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.. 2022 ,	0
369	NMR Molecular Replacement Provides New Insights into Binding Modes to Bromodomains of BRD4 and TRIM24.. 2022 ,	
368	Dynamic nucleosome organization after fertilization reveals regulatory factors for mouse zygotic genome activation.	
367	Inhibition of histone readers bromodomain extra-terminal proteins alleviates skin fibrosis in experimental models of scleroderma.. 2022 ,	0
366	Comparing the Performance of Different AMBER Protein Forcefields, Partial Charge Assignments, and Water Models for Absolute Binding Free Energy Calculations.. 2022 ,	1
365	The emerging role of mass spectrometry-based proteomics in drug discovery.. 2022 ,	10
364	BET proteins are essential for the specification and maintenance of the epiblast lineage in mouse preimplantation embryos.. 2022 , 20, 64	0
363	The landscape of pioneer factor activity reveals the mechanisms of chromatin reprogramming and genome activation.. 2022 ,	2
362	Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.. 2022 ,	
361	BET in hematologic tumors: immunity, pathogenesis, clinical trials and drug combinations. 2022 ,	0
360	MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. 2022 , 2, 182-201	1
359	Therapeutic targets for cardiac fibrosis: from old school to next-gen.. 2022 , 132,	4
358	AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells.. 2022 , 10, 853652	0
357	Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). 2022 ,	

356	Research progress on antineoplastic, antibacterial, and anti-inflammatory activities of seven-membered heterocyclic derivatives.. 2022,	0
355	Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment.. 2022, 15,	0
354	Targeting radioresistance and replication fork stability in prostate cancer.. 2022,	0
353	BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer.. 2022, 11,	1
352	Structure-Based Discovery and Optimization of Furo[3,2-]pyridin-4(5)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.. 2022,	0
351	Triterpenoids as Reactive Oxygen Species Modulators of Cell Fate.. 2022,	0
350	BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade.	
349	A Nutrient-Based Cellular Model to Characterize Acetylation-Dependent Protein-Protein Interactions.. 2022, 9, 831758	0
348	Alchemical Free Energy Methods Applied to Complexes of the First Bromodomain of BRD4.. 2022,	2
347	Chemical Biology Approaches to Identify and Profile Interactors of Chromatin Modifications.. 2022,	0
346	Degradation and Inhibition of Epigenetic Regulatory Protein BRD4 Exacerbate Alzheimer's Disease-Related Neuropathology in Cell Models.. 2022, 101794	1
345	RNA decay defines the therapeutic response to transcriptional perturbation in cancer.	
344	NSMCE2, a Novel Super-Enhancer Regulated Gene, is Linked to Poor Prognosis and Therapy Resistance in Breast Cancer.	
343	The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden.. 2022, 153, 155839	0
342	BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.. 2022, 604, 63-69	3
341	Discovery of a highly potent CECR2 bromodomain inhibitor with 7H-pyrrolo[2,3-d] pyrimidine scaffold.. 2022, 123, 105768	0
340	Domain-selective BET inhibition attenuates transcriptional and behavioral responses to cocaine.. 2022, 109040	1
339	The fission yeast bromodomain protein Bdf2 is required for growth of cells with circular chromosomes.. 2021,	0

338	Dihydropyridine Lactam Analogs Targeting BET Bromodomains.. 2021 , e202100407	
337	Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors.. 2021 , 27,	0
336	Histone Modifications and Their Targeting in Lymphoid Malignancies.. 2021 , 23,	1
335	Discovery of Novel BRD4 Ligand Scaffolds by Automated Navigation of the Fragment Chemical Space.. 2021 ,	0
334	KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. 2021 , 12, 7204	5
333	CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation.	
332	A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader.	
331	BET Proteins Regulate Expression of Osr1 in Early Kidney Development.. 2021 , 9,	
330	Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.. 2021 ,	1
329	Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity. 2021 ,	9
328	NUT carcinoma in children, adolescents and young adults.. 2022 ,	0
327	A combinatorial anticancer drug screen identifies off-target effects of epigenetic chemical probes.	
326	Report of the First International Symposium on NUT Carcinoma.. 2022 ,	1
325	Proteolysis-targeting chimeras (PROTACs) in cancer therapy.. 2022 , 21, 99	4
324	Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.. 2022 ,	0
323	Nutritional Epigenetics in Cancer.. 2022 ,	0
322	Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects.. 2022 , 13, 849451	0
321	Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.. 2022 ,	2

320	Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.. 2022 , 15, 44	2
319	Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer.. 2022 , 13, 878740	1
318	Dynamic nucleosome organization after fertilization reveals regulatory factors for mouse zygotic genome activation.. 2022 ,	1
317	The paradigm of drug resistance in cancer: an epigenetic perspective.. 2022 , 42,	2
316	Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic.. 2022 ,	2
315	Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering.. 2022 , 47, 417-432	0
314	BET bromodomain inhibitors.. 2022 , 68, 102148	4
313	Data_Sheet_1.pdf. 2020 ,	
312	Table_1.DOCX. 2020 ,	
311	Table_2.DOCX. 2020 ,	
310	Image_1.pdf. 2020 ,	
309	Image_2.pdf. 2020 ,	
308	Image_3.pdf. 2020 ,	
307	Image_1.jpg. 2020 ,	
306	Image_2.jpg. 2020 ,	
305	Image_3.jpg. 2020 ,	
304	Image_4.jpg. 2020 ,	
303	Table_1.xlsx. 2020 ,	

302 Data_Sheet_1.pdf. **2018,**

301 Table_1.XLSX. **2018,**

300 Table_2.XLSX. **2018,**

299 Table_3.XLSX. **2018,**

298 Table_4.XLSX. **2018,**

297 Table_5.XLSX. **2018,**

296 Table_6.pdf. **2018,**

295 Table_7.xlsx. **2018,**

294 Data_Sheet_1.PDF. **2019,**

293 Data_Sheet_1.docx. **2019,**

292 DataSheet_1.pdf. **2020,**

291 Data_Sheet_1.docx. **2020,**

290 Presentation_1.pdf. **2020,**

289 Image_1.TIF. **2020,**

288 Image_2.TIF. **2020,**

287 Image_3.TIF. **2020,**

286 Data_Sheet_1.doc. **2019,**

285 R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.. **2022, 1**

- 284 Chromatin profiling in human neurons reveals aberrant roles for histone acetylation and BET family proteins in schizophrenia.. **2022**, 13, 2195 3
- 283 Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumor.. **2022**, 1
- 282 Synergistic blocking of RAS downstream signaling and epigenetic pathway in mutant pancreatic cancer.. **2022**, 14, 0
- 281 Rare Sinonasal and Skull Base Tumors. **2022**, 249-268
- 280 NUT Carcinoma. **2022**, 193-204
- 279 Basicity-Tuned Selectivity: Synthesis of Benzimidazolone and Benzodiazepine from N-Alkyl-N-(2-(pyridin-2-ylamino)-phenyl)formamides. **2022**, 42, 1146
- 278 It's a DoG-eat-DoG world-altered transcriptional mechanisms drive downstream-of-gene (DoG) transcript production.. **2022**, 0
- 277 Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors.. **2022**, 1
- 276 Transcription Pause and Escape in Neurodevelopmental Disorders. **2022**, 16,
- 275 IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma.. **2022**, 13, 2420 0
- 274 Validation of BET proteins as therapeutic targets in Neurofibromatosis type 2.
- 273 Cross-Talk Between Histone Methyltransferases and Demethylases Regulate REST Transcription During Neurogenesis. **2022**, 12,
- 272 Emerging roles of BET proteins in transcription and co-transcriptional RNA processing.. **2022**, e1734 1
- 271 Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury.. **2022**, 1 0
- 270 Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.. **2022**,
- 269 Dual HDACBRD4 inhibitors endowed with antitumor and antihyperalgesic activity. 1
- 268 DDB1 prepares brown adipocytes for cold-induced thermogenesis.
- 267 The prognostic significance of bromodomain protein 4 expression in solid tumor patients: A meta-analysis.. **2022**, 234, 153918

266	Discovery of novel benzimidazole derivatives as potent p300 bromodomain inhibitors with anti-proliferative activity in multiple cancer cells.. 2022 , 66, 116784	0
265	PROTACs: Novel approach for cancer breakdown by breaking proteins.. 2022 , 120577	0
264	Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.. 2022 , 215716	2
263	Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.. 2022 , 238, 114423	2
262	Respiratory Tract and Mediastinum. 2014 , 59-104	2
261	cMYC protein interactions and chromatin association in NUT carcinoma.	
260	Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment. 2022 , 151, 113116	1
259	Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. 2022 , 119,	1
258	Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. 2022 , 15, 665	0
257	BRD4 promotes resection and homology-directed repair of DNA double-strand breaks. 2022 , 13,	1
256	Major Clinical Response in a Patient with Leukemia Cutis Treated with the Bromodomain Inhibitor PLX51107 and Azacitidine. 2022 , 119, 106884	
255	Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins.	
254	Discovery of CECR2 Bromodomain Inhibitors with High Selectivities over BPTF Bromodomain.	
253	NUT Carcinoma, an under-recognized malignancy: a clinicopathologic and molecular series of 6 cases showing a subset of patients with better prognosis and a rare ZNF532::NUTM1 fusion. 2022 ,	0
252	The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer.	
251	A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader. 2022 ,	1
250	Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins.	0
249	BRD2 interconnects with BRD3 to facilitate Pol II transcription initiation and elongation to prime promoters for cell differentiation. 2022 , 79,	0

248	BacPROTACs mediate targeted protein degradation in bacteria. 2022 ,	3
247	Differential cofactor dependencies define distinct types of human enhancers. <i>Nature</i> ,	50.4 2
246	Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma. 2022 , 14, 2761	0
245	Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. 2022 , 927, 175071	0
244	Identification of (S)-10-Hydroxycamptothecin as a potent BRD4 inhibitor for treating triple-negative breast cancer. 2022 , 1265, 133366	
243	RNase H1, the Gold Standard for R-Loop Detection. 2022 , 91-114	1
242	PROTACs: past, present and future. 2022 , 51, 5214-5236	16
241	PROTACs for BRDs proteins in cancer therapy: a review. 2022 , 37, 1694-1703	5
240	The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. 12,	0
239	Epigenetic Regulation of Inflammatory Signaling and Inflammation-Induced Cancer. 10,	0
238	BacPROTACs to basics: Targeted protein degradation in bacteria. 2022 , 185, 2203-2205	0
237	Signal pathways and precision therapy of small-cell lung cancer. 2022 , 7,	1
236	Expansion microscopy allows high resolution single cell analysis of epigenetic readers.	1
235	Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures. 2022 , 15, 745	0
234	Tiny Titans - Nanobodies as Powerful Tools for TR-FRET Assay Development.	1
233	Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators. 2022 , 152, 113230	1
232	Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors. 2022 , 127, 105917	
231	Taohong Siwu Decoction exerts anticancer effects on breast cancer via regulating MYC, BIRC5, EGF and PIK3R1 revealed by HTS2 technology. 2022 , 20, 3461-3472	0

230	Innovation in Pharmaceutical Assistance. 58,	
229	Gpx3 and Egr1 Are Involved in Regulating the Differentiation Fate of Cardiac Fibroblasts under Pressure Overload. 2022 , 2022, 1-21	0
228	Inhibition of BET Family Proteins Suppresses African Swine Fever Virus Infection.	0
227	Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood-brain barrier integrity. 2022 , 19,	3
226	A gene expression biomarker identifies inhibitors of two classes of epigenome effectors in a human microarray compendium. 2022 , 110032	
225	Learning the chemical grammar of biomolecular condensates.	2
224	A Young Male Patient with Nuclear Protein in Testis Carcinoma of the Thorax. 2022 , 62, 227-234	
223	Development of Rapid and Facile Solid-Phase Synthesis of PROTACs via a Variety of Binding Styles. 2022 , 11,	0
222	BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph + chronic myeloid leukemia.	3
221	Cerebral organoids as an in vitro model to study autism spectrum disorders.	1
220	Catching Nucleosome by Its Decorated Tails Determines Its Functional States. 13,	
219	Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. 2022 ,	0
218	Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation.	0
217	TRPM3-Induced Gene Transcription Is under Epigenetic Control. 2022 , 15, 846	
216	Liquid-liquid phase separation in tumor biology. 2022 , 7,	1
215	Applications and Limitations of Oxime-Linked Split PROTACs	0
214	ROR1 plays a critical role in pancreatic tumor-initiating cells with a partial EMT signature.	
213	BRD4 and MYC : Power couple in Transcription and Disease.	3

212	NUT Carcinoma An Underdiagnosed Malignancy. 12,	0
211	Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs). 2022 , 32, 419-432	
210	Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. 13,	1
209	Acetylation-Specific Interference by Anti-Histone H3K9ac Intrabody Results in Precise Modulation of Gene Expression. 2022 , 23, 8892	0
208	Multiple Myeloma Therapy: Emerging Trends and Challenges. 2022 , 14, 4082	1
207	Emerging epigenetic therapies of cardiac fibrosis and remodeling in heart failure: from basic mechanisms to early clinical development.	0
206	Identification of the NRF2 transcriptional network as a therapeutic target for trigeminal neuropathic pain. 2022 , 8,	0
205	Key Considerations in Targeted Protein Degradation Drug Discovery and Development. 10,	1
204	An Epigenetic Role of Mitochondria in Cancer. 2022 , 11, 2518	5
203	Discovery of BET specific bromodomain inhibitors with a novel scaffold. 2022 , 116967	
202	Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog Pathway Inhibitor-1.	
201	Nested epistasis enhancer networks for robust genome regulation.	2
200	Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.	
199	Small molecule photocatalysis enables drug target identification via energy transfer. 2022 , 119,	1
198	JQ-1 ameliorates schistosomiasis liver granuloma in mice by suppressing male and female reproductive systems and egg development of <i>Schistosoma japonicum</i> . 2022 , 16, e0010661	0
197	BRPF1-KAT6A/KAT6B Complex: Molecular Structure, Biological Function and Human Disease. 2022 , 14, 4068	0
196	Widespread hydroxylation of unstructured lysine-rich protein domains by JMJD6. 2022 , 119,	0
195	The contemporary management of cancers of the sinonasal tract in adults.	1

194	Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma. 2022 , 119,	0
193	Use of Phosphazene Base BTPP for Phosphorylative Activation in the Scale-Up of BET Inhibitor GSK525762.	
192	BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia. 2022 , 2022, 1-18	2
191	Enantioselective Approach for Expanding the Three-Dimensional Space of Tetrahydroquinoline to Develop BET Bromodomain Inhibitors**.	
190	1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains.	
189	Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.	0
188	Epigenetic reader SP140 loss of function drives Crohn's disease due to uncontrolled macrophage topoisomerases. 2022 , 185, 3232-3247.e18	1
187	Establishment and evaluation of a dual HDAC / BET inhibitor as a therapeutic option for germ cell tumors and other urological malignancies.	0
186	Radius measurement via super-resolution microscopy enables the development of a variable radii proximity labeling platform. 2022 , 119,	2
185	Catching BETs by viruses. 2022 , 1865, 194859	
184	A small proportion of X-linked genes contribute to X chromosome upregulation in early embryos via BRD4-mediated transcriptional activation. 2022 ,	0
183	N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β cells. 13,	0
182	JQ1 attenuates neuroinflammation by inhibiting the inflammasome-dependent canonical pyroptosis pathway in SAE. 2022 , 189, 174-183	2
181	Role of nitric oxide in hyper-aggressiveness of tumor cells that survive various anti-cancer therapies. 2022 , 179, 103805	1
180	Design, synthesis and biological evaluation of coumarin derivatives as potential BRD4 inhibitors. 2022 , 128, 106117	0
179	PROTACs bearing piperazine-containing linkers: what effect on their protonation state?. 2022 , 12, 21968-21977	
178	Attenuating iPSC Reprogramming Stresses with Dominant Negative BET Peptides.	0
177	A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain. 2022 , 58, 9654-9657	1

- 176 Epigenetic Events in Lung Cancer. **2022**, 0
- 175 PROTAC degraders as chemical probes for studying target biology and target validation. **2022**, 51, 7971-7993 1
- 174 Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. **2022**, 51, 8216-8257 5
- 173 BRD4: a general regulator of transcription elongation. **2022**, 13, 70-81 0
- 172 Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases. **2022**, 15, 1032 0
- 171 Development of an N-Terminal BRD4 Bromodomain-Targeted Degradator. 0
- 170 Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. 0
- 169 Super-enhancer-controlled positive feedback loop BRD4/ERBETB β promotes ER β positive breast cancer. 0
- 168 Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN. 10, 0
- 167 Drug interaction mapping with proximity dependent enzyme recruiting chimeras. 0
- 166 Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma. **2022**, 27, 1110-1121 0
- 165 MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment. **2022**, 14, 4421 0
- 164 Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach. **2022**, 14, 4691 1
- 163 An interplay between BRD4 and G9a regulates skeletal myogenesis. 10, 0
- 162 The p300/CBP inhibitor A485 normalizes psoriatic fibroblast gene expression in vitro and reduces psoriasis-like skin inflammation in vivo. **2022**, 0
- 161 Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond. 13, 1
- 160 Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain. 0
- 159 Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications. **2022**, 12, 9674 0

158	Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1.	5
157	TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities. 2022,	0
156	A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2. 2022, 14, 2150	0
155	Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma. 12,	0
154	Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9).	0
153	A comprehensive review of BET-targeting PROTACs for cancer therapy. 2022, 73, 117033	0
152	Epigenomic Measurements in Brain Tissues. 2022, 3221-3261	0
151	Emerging degrader technologies engaging lysosomal pathways. 2022, 51, 8832-8876	1
150	BRD4: quantum mechanical protein-ligand binding free energies using the full-protein DFT-based QM-PBSA method. 2022, 24, 25240-25249	0
149	The role of Interleukin 36 in the Epithelial-Mesenchymal Transition process of Chronic Rhinosinusitis: a pilot study.	0
148	NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. 2022, 22,	1
147	Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: Design, synthesis, and biological evaluations. 2022, 107923	0
146	Epigenetic mechanisms of cadmium-induced nephrotoxicity. 2022, 100372	0
145	YAP condensates are highly organized hubs for YAP/TEAD transcription.	0
144	NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations. Publish Ahead of Print,	0
143	SETD6 Regulates E2-Dependent Human Papillomavirus Transcription.	0
142	Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility. 2022, 61, 2303-2318	0
141	The Relevance of DNA Methylation and Histone Modification in Periodontitis: A Scoping Review. 2022, 11, 3211	1

- 140 The multivalent G-quadruplex (G4)-ligands MultiTASQs allow for versatile click chemistry-based investigations. ○
- 139 The E3 Ligases in Cervical Cancer and Endometrial Cancer. **2022**, 14, 5354 ○
- 138 Transcriptional plasticity of fibroblasts in heart disease. **2022**, 50, 1247-1255 ○
- 137 Viral Hijacking of BET Proteins. **2022**, 14, 2274 ○
- 136 DNA-encoded library (DEL)-enabled discovery of proximity-inducing small molecules. 2
- 135 Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML. ○
- 134 Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma. **2022**, 13, 2013 ○
- 133 Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. **2023**, 475, 214899 ○
- 132 Identification of novel BRD4 inhibitors by pharmacophore screening, molecular docking, and molecular dynamics simulation. **2023**, 1274, 134363 ○
- 131 Study on the interaction of the bromodomain inhibitor JQ1 with human serum albumin by spectroscopic and molecular docking studies. **2023**, 1273, 134374 ○
- 130 Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites-Halogenated Probes of Druglike and Peptide-like Molecular Interactions. ○
- 129 Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. **2022**, 23, 13657 ○
- 128 Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. **2022**, 15, 1366 2
- 127 Epigenetic alterations fuel brain metastasis via regulating inflammatory cascade. **2022**, ○
- 126 IL-1 β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. ○
- 125 Modulation of Virulence-Associated Traits in *Aspergillus fumigatus* by BET Inhibitor JQ1. **2022**, 10, 2292 ○
- 124 A Comprehensive Picture of Biotransformation in Drug Discovery. **2022**, 41-101 ○
- 123 Fragment Linker Prediction Using Deep Encoder-Decoder Network for PROTAC Drug Design. ○

122	Aging tumour cells to cure cancer: Pro-senescence therapy for cancer. 2017 , 147, w14367	4
121	The era of high-quality chemical probes. 2022 , 13, 1446-1459	0
120	Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric BRD4 inhibitor/nitric oxide-donator. 2023 , 246, 114970	0
119	Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. 2023 , 364, 10-19	0
118	Design, synthesis, and biological evaluation of BRD4 degraders. 2023 , 78, 117134	0
117	Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury. 2023 , 247, 115023	0
116	Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression.	0
115	Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer. 12,	0
114	Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation.	0
113	BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target. 12,	1
112	Gene activation guided by nascent RNA-bound transcription factors. 2022 , 13,	0
111	T-cell acute lymphoblastic leukemia: Promising experimental drugs in clinical development.	0
110	Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras. 2022 , 8,	0
109	Multifunctional Photo-Cross-Linking Probes: From Target Protein Searching to Imaging Applications.	0
108	Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy. 14, 2340-2352	0
107	Targeted Protein Degradation: Clinical Advances in the Field of Oncology. 2022 , 23, 15440	1
106	A novel lncRNA MDHDH suppresses glioblastoma multiforme by acting as a scaffold for MDH2 and PSMA1 to regulate NAD ⁺ metabolism and autophagy. 2022 , 41,	1
105	The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer's Disease. 2023 , 24, 13	1

104	Characterization of the Functional Interplay between the BRD7 and BRD9 Homologues in mSWI/SNF Complexes.	0
103	Rewiring Cancer Drivers to Activate Apoptosis.	0
102	Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, window of opportunity study.	1
101	Regulation of programmed cell death by Brd4. 2022 , 13,	0
100	BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. 2022 , 13,	1
99	Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation. 2023 , 28, 3	0
98	Discovery and characterization of cyclic peptides selective for the C-terminal bromodomains of BET family proteins.	0
97	Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation. 1-13	0
96	BET Inhibitors Induce p53-Independent Growth Arrest in HCT116 Cells & via; Epigenetic Control of the E2F1/c-MYC Axis. 2023 , 46, 12-18	0
95	Recent advances in epigenetic anticancer therapeutics and future perspectives. 13,	0
94	Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells. 11,	0
93	A proteome-wide atlas of drug mechanism of action.	0
92	Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design.	0
91	Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification. 2023 , 15, 466	0
90	The epigenetic regulator BRD4 is required for myofibroblast differentiation of knee fibroblasts.	0
89	Chromatin Remodeling Drives Immune-Fibroblast Crosstalk in Heart Failure Pathogenesis.	0
88	Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. 2023 , 19, e1011089	0
87	Chemical inhibition of bromodomain proteins in insect stage African trypanosomes perturbs silencing of the Variant Surface Glycoprotein repertoire and results in widespread changes in the transcriptome.	0

86	Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. 2023 , 38,	1
85	BET/DAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis.	0
84	Characterizing crosstalk in epigenetic signaling to understand disease physiology. 2023 , 480, 57-85	0
83	CJ2: A Novel Potent Platinum(IV) Prodrug Enhances Chemo-Immunotherapy by Facilitating PD-L1 Degradation in the Cytoplasm and Cytomembrane. 2023 , 66, 875-889	0
82	Emerging Epigenetic-Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment. 2206169	1
81	MYC enhancer invasion promotes prognostic cancer type-specific gene programs through an epigenetic switch.	0
80	Attenuating iPSC reprogramming stress with dominant-negative BET peptides. 2023 , 26, 105889	0
79	Innate Immunity in Cardiovascular Diseases Identification of Novel Molecular Players and Targets. 2023 , 12, 335	0
78	Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. 2023 , 247, 115077	0
77	BET inhibitors enhance the anti-cancer effect of etoposide by suppressing the MRN-ATM axis in the DNA damage response. 2022 ,	0
76	It Runs in the Bromodomain Family: Speckled Proteins (SP) Play a Role in the Antitumor Immune Response in Solid Tumors. 2023 , 24, 549	0
75	Synthesis, Biochemical Characterization, and Genetic Encoding of a 1,2,4-Triazole Amino Acid as an Acetyllsine Mimic for Bromodomains of the BET Family.	1
74	Protein acylation: mechanisms, biological functions and therapeutic targets. 2022 , 7,	0
73	Physachenolide C is a Potent, Selective BET Inhibitor. 2023 , 66, 913-933	0
72	Targeting super enhancers for liver disease: a review. 11, e14780	0
71	Bromodomain-containing Protein 4 Regulates Innate Inflammation in Airway Epithelial Cells via Modulation of Alternative Splicing.	0
70	Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. 2023 , 201-235	0
69	Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition.	0

- 68 BRD4-PRC2 represses transcription of T-helper 2-specific negative regulators during T-cell differentiation. ○
- 67 Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition. **2023**, 13, ○
- 66 A Case of Nuclear Protein of the Testis Midline Carcinoma Diagnosed by Staging Laparoscopy for a Descending Colon Tumor with Peritoneal Dissemination. **2023**, 56, 27-33 ○
- 65 A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle. **2023**, 28, 1141 ○
- 64 Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence. **2023**, 145, 2711-2732 ○
- 63 Histone acetylation insulator SET orchestrates PP2A inhibition and super-enhancer activation. ○
- 62 BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. **2023**, 91-97 ○
- 61 BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells. ○
- 60 Super-enhancer driven expression of BAHCC1 promotes melanoma cell proliferation and genome stability. ○
- 59 Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease. **2023**, ○
- 58 Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography. **2023**, 59, 3126-3129 ○
- 57 The bromodomain inhibitor JQ1 is a molecular glue targeting centromeres. ○
- 56 An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review. **2023**, 14, 873 ○
- 55 Discovery of BRD4/HDAC Dual Inhibitors with Improved Fungal Selectivity and Potent Synergistic Antifungal Activity against Fluconazole-Resistant *Candida albicans*. ○
- 54 Development of a sensitive luminescent probe to uncover new BRD4 inhibitors in living cells. **2023**, 463, 142356 ○
- 53 Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer. **2023**, 135, 106495 ○
- 52 From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors. **2023**, 251, 115246 ○
- 51 Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections. **2023**, 197, 114819 ○

- 50 TAF1 bromodomain inhibition as a candidate epigenetic driver of congenital heart disease. **2023**, 1869, 166689 ○
- 49 Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity. **2023**, 160, 114353 ○
- 48 CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degradation via Recruitment of DCAF16. **2023**, 18, 331-339 ○
- 47 Fragment expansion with NUDELS - poised DNA-encoded libraries. ○
- 46 Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition. **2023**, 230, 123428 ○
- 45 PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. **2023**, 28, 1217 ○
- 44 Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics. **2023**, 27, 1-7 ○
- 43 BET Bromodomain Degradation Disrupts Function but Not 3D Formation of RNA Pol2 Clusters. **2023**, 16, 199 ○
- 42 BET proteins: Biological functions and therapeutic interventions. **2023**, 243, 108354 ○
- 41 Targeting fungal BET bromodomains as anti-Candida antifungal strategy. ○
- 40 Translocations and Gene Fusions in Sinonasal Malignancies. **2023**, 25, 269-278 ○
- 39 Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2/BRD4 Inhibitor for the Treatment of Some Solid Tumors. **2023**, 66, 2646-2662 ○
- 38 An intramolecular bivalent degrader glues an intrinsic BRD4-DCAF16 interaction. ○
- 37 Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders. ○
- 36 Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review. **2023**, 102, e32904 ○
- 35 Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation. **2023**, 31, 717-729 ○
- 34 E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology. **2023**, 66, 3173-3194 ○
- 33 Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach. 1-16 ○

- 32 Inhibitors targeting epigenetic modifications in cancer. **2023**, 287-324 ○
- 31 Abiotic peptides as carriers of information for the encoding of small-molecule library synthesis. **2023**, 379, 939-945 1
- 30 Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation. **2023**, 11, 750 1
- 29 mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. **2023**, 8, ○
- 28 METTL14 promotes fibroblast-like synoviocytes activation via the LASP1/SRC/AKT axis in RA. ○
- 27 Development and applications of chimera platforms for tyrosine phosphorylation. ○
- 26 Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor. **2023**, 86, 129220 ○
- 25 Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins. **2023**, 18, e0280645 ○
- 24 BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300/H3K27ac/PLK1 axis. **2023**, 210, 115497 ○
- 23 BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. **2023**, 14, ○
- 22 Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy. **2023**, 24, 5665 ○
- 21 Effect of BRD4 Inhibitor on Cognitive Deficit and c-Fos /BDNF level in rats with Alzheimer's disease. ○
- 20 Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer. **2023**, 80, ○
- 19 Targeted Protein Degradation through E2 Recruitment. **2023**, 18, 897-904 ○
- 18 The effects of MYC on tumor immunity and immunotherapy. **2023**, 9, ○
- 17 Recent progress and structural analyses of domain-selective BET inhibitors. ○
- 16 Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer. **2023**, 15, 2036 ○
- 15 PROTACing oncoproteins: targeted protein degradation for cancer therapy. **2023**, 22, ○

- 14 Bromodomain protein BRD8 regulates cell cycle progression in colorectal cancer cells through a TIP60-independent regulation of the pre-RC complex. **2023**, 26, 106563
- 13 Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. **2023**, 17,
- 12 Tracking chromatin state changes using nanoscale photo-proximity labelling. **2023**, 616, 574-580
- 11 Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC).
- 10 Rapid-kinetics degron benchmarking reveals off-target activities and mixed agonism-antagonism of MYB inhibitors.
- 9 Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation. **2023**, 24, 7017
- 8 Rational Chemical Design of Molecular Glue Degraders.
- 7 R-Loops and R-Loop-Binding Proteins in Cancer Progression and Drug Resistance. **2023**, 24, 7064
- 6 BRD4: New hope in the battle against glioblastoma. **2023**, 191, 106767
- 5 Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
- 4 Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. **2023**, 15,
- 3 Open resources for chemical probes and their implications for future drug discovery. 1-9
- 2 Experimental Validation and Prediction of Super-Enhancers: Advances and Challenges. **2023**, 12, 1191
- 1 Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization. **2023**, 115393